100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead from Damon Runyon Broadway THE SCIENCE OF Tickets and our endowment. For more information, visit: WWW.DAMONRUNYON.ORG/GET-INVOLVED LEADERSHIP

Annual Report 2018

ONE EXCHANGE PLAZA 55 Broadway, Suite 302 New York, New York 10006 1.877.7CANCER T 212.455.0500 F 212.455.0509 www.damonrunyon.org

348814_DRC_Book_CVR_R1.indd 1-3 10/25/18 8:34 PM Financial Summary Fiscal Year 2018

As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2018.

For our complete audited financial statements, please visit our website at WWW.DAMONRUNYON.ORG

TOTAL OPERATING EXPENSES TOTAL REVENUE

$22 $22 MILLION MILLION

Award Programs 83.5% Contributions 56.2% Fundraising 14.0% Damon Runyon Broadway Tickets 3.3% General Administration 2.5% Donated Services 3.7% Bequests and Trusts 8.3% Misc. Income 1.0% Allocation from Investments 27.5%

2017 2018 SUMMARY OF Total Assets $142,411,870 $148,707,992 BALANCE SHEETS Total Liabilities $30,256,220 $32,236,227 Total Net Assets $112,155,650 $116,471,765

Our overhead is paid from our endowment and Damon Runyon Broadway Tickets, allowing 100% of your donation to support cancer research.

348814_DRC_Book_CVR_R1.indd 4-6 10/25/18 8:34 PM Leadership is at the core of our mission. We do not simply fund cancer research. We identify and enable new generations of future scientific leaders capable of discovering radical new approaches to how we prevent, diagnose and cure the many forms of cancer.

We do this because it will take exceptional people to ultimately defeat a disease as pernicious and wily as cancer. We select these young scientists with great care and provide them with funding, mentorship, and support. They then go on to lead the most innovative and paradigm-shifting research—research that has saved and will continue to save lives.

At the end of this year, our current Runyon, it is fitting that the theme of this President and Chief Executive Officer, year’s annual report is leadership. Lorraine W. Egan, is stepping down after In the pages that follow, we share our 18 years at the helm of the Damon Runyon thoughts on leadership and how we are Cancer Research Foundation. paving the way for new breakthroughs She will be succeeded by Yung S. Lie, PhD, against cancer by finding and fostering the our Deputy Director and Chief Scientific scientific leaders who will make the end of Officer. At this momentous time for Damon all suffering from cancer a reality.

2018 ANNUAL REPORT 1 INTRODUCING Our Next Leader

When our Fellowship Award Committee selected Yung S. Lie, PhD, as a Damon Runyon Fellow in 2000, little did they know that they were picking Damon Runyon’s future President and CEO. She will be the first scientist and alumna to lead the organization since it was founded in 1946.

Dr. Lie received her BA degree from UC Berkeley and her PhD from Stanford University. As a Damon Runyon Fellow from 2001-2004, Dr. Lie studied how cells migrate and navigate their environment at the University of California, San Francisco and The . She joined Damon Runyon in 2008 and currently serves as its Deputy Director and Chief Scientific Officer. Under her leadership, Damon Runyon scientists have pioneered the fields of immunotherapy, genomic and precision medicine; its award programs have expanded to target the greatest areas of need in cancer research; and Damon Runyon’s research funding has grown by 225%, to more than $18 million annually.

Dr. Lie’s postdoctoral mentor, Mary Beth Hatten, PhD, Professor at The Rockefeller University and member of the National Academy of Sciences, calls her “a superb scientist and astute judge of scientific talent. Congratulations to Damon Runyon on an outstanding choice to lead their organization.”

2 DAMON RUNYON CANCER RESEARCH FOUNDATION LORRAINE W. EGAN: EIGHTEEN YEARS OF EXTRAORDINARY LEADERSHIP

The Damon Runyon Cancer Research Foundation is grateful to Lorraine W. Egan for her leadership for the past eighteen years. Thousands of scientists have been funded during her tenure, and they have contributed significantly In the scientific community, to accelerating progress Damon Runyon is held in the highest against cancer during this century. She has esteem for its commitment to built a deeply committed community of supporters young scientists and rigor in who have enabled Damon Runyon to expand its selecting the best of the best. I am research funding and develop new programs thrilled and honored to continue to ensure that the best this important work and am young minds have the resources they need confident that it will lead to new to pursue bold ideas. “Lorraine has set the gold breakthroughs against cancer. standard for leadership,” says Damon Runyon Board Chair Alan M. Leventhal. “Her commitment to our YUNG S. LIE, Ph D scientists, keen ability to inspire others, and above all, relentless drive to end cancer will have a lasting impact.”

2018 ANNUAL REPORT 3 EXECUTIVE Q&A Reflections on Leadership

The following are edited excerpts Lorraine, what makes Damon Runyon from an interview with Lorraine a leader in cancer research? W. Egan, current President of the Damon Runyon Cancer Lorraine: The most important thing that comes to mind when I Research Foundation, and her think about Damon Runyon is its commitment to excellence. We successor, Yung S. Lie, PhD. For stand for excellence in the science that we fund, but also in terms of video of the full interview, visit how we run our organization and steward our donors’ gifts. Our www.damonrunyon.org. donors are incredibly generous to support us and we take that very seriously. Our Board of Directors looks for excellence in the people to lead the organization. I’m honored that they selected me years ago and now it’s incredible for me to pass the baton to somebody who is, first of all, a Damon Runyon alumna and, secondly, clearly the right person to lead Damon Runyon going forward. It’s the ultimate success that we can have a seamless transition and maintain the quality and excellence of our organization.

4 DAMON RUNYON CANCER RESEARCH FOUNDATION As a scientist and former award recipient, Yung is the ideal person to lead our organization. She completely understands our mission. She understands the science. I can’t think of a better person to take the helm of Damon Runyon.

LORRAINE W. EGAN

What makes Yung the best Lorraine: The science is moving so fast and choice to lead Damon Runyon? the discoveries are incredible. It’s possible that during Yung’s tenure as CEO tremendous Lorraine: It’s exciting for me to be able to hand breakthroughs will be made in cancer and more off the leadership to such a perfect person. and more people’s lives will be saved. I’ll be a Damon Runyon is all about the science. It is more little jealous not to be at the helm for that. important to us than anything, that we fund the best scientists doing paradigm-shifting work. As a female scientist yourself, As a scientist and former award recipient, Yung can you talk about some of the is the ideal person to lead our organization. challenges that female scientists have? She completely understands our mission. She understands the science. I can’t think of a better Yung: Science is a particularly challenging person to take the helm of Damon Runyon. career path for everyone, but we know that for women it is especially difficult to balance a very As the outgoing CEO of Damon Runyon, demanding career with having a young family what advice do you have for her? and trying to be successful in all aspects of their lives. At Damon Runyon, we try to support our Lorraine: I’m not sure Yung needs any advice women scientists in ways that help them get because she’s so incredibly talented, but what has through these times that can be very difficult. made us a good team, and what she’ll carry on, is We help by providing all of our scientists who staying focused on our mission. It’s all about the have young children with a childcare allowance science and the scientists. If we stay true to that, and also provide women with additional no matter where the science goes and what new resources to bring their children to our retreats, discoveries are made, funding brilliant people is for example. We can also be mentors and provide always going to be the secret to success. additional support and advice as they need it.

Yung, what are you particularly Are you ready to take the helm? excited about moving forward Yung: I feel very excited, honored and confident in this new role? about stepping into this new role as the CEO at Damon Runyon. In part, it’s because of the deep Yung: We are funding more research and history and experience that I’ve had with Damon more scientists than ever before, and there’s Runyon—having been a Fellow myself and then the capacity to do more. I’m excited about leading the scientific programs for so many the opportunity to work with our scientific years. Lorraine has been an incredible person to leadership to identify the right places for Damon work with and to learn from, and so I do feel that Runyon to fund more cancer research to make a I’m in the absolute best position to now move greater impact. into this role.

2018 ANNUAL REPORT 5 OUR SCIENTISTS The Science of Identifying Future Leaders

Twelve scientists funded by Damon Runyon have received the Nobel Prize. Seventy-four are members of the prestigious National Academy of Sciences. Countless others are behind recent progress in precision medicine and immunotherapy, and spearheading promising and diverse new fields of research.

What is behind this stellar track record in “Clearly our peer review process has to be choosing future leaders? Award selection spectacular. You need exceptional people committees that are as creative, risk-taking evaluating these individuals and their and scientifically diverse as the candidates proposals because we are seeking the best they evaluate. and brightest people.”

The world-renowned scientists on Damon For our junior faculty awards, finalists must Runyon’s award committees hail from the pitch their proposals in person, a dynamic nation’s most prestigious research organizations process that allows committee members to and academic institutions. They are laser- interact with applicants in real time. Are they focused on selecting the most brilliant young fearless, willing to push outside of their comfort scientists and providing the support needed to zone, or are they going to take the obvious turn their high-risk ideas into breakthroughs path? “We like people who ask big, important, against cancer. interesting questions, and they have to be courageous in the way they pursue them.” For William G. Kaelin, Jr., MD, Damon Runyon Board Member and Vice Chair of Scientific The award selection committees also think Programs, a rigorous selection process is key to broadly about the best science to fund. As Dr. identifying these rising . Kaelin observes, “You can’t always predict what

6 DAMON RUNYON CANCER RESEARCH FOUNDATION the outcomes of the work are going to be. The new methods and doesn’t ask hard questions,” person who’s working on breast cancer might says Dr. Green. break the back of some other cancer problem This explains why Damon Runyon alumni unrelated to breast cancer.” dominate the biomedical ecosystem—running Rachel Green, PhD, Chair of the Fellowship top-tier research laboratories, publishing Award Committee and also a former Damon landmark studies and founding biotech Runyon Fellow, says, “Our role is to do our very companies to move their discoveries to patients. best to help come up with a balanced set of views on the committee. That really does enable Dr. Kaelin emphasizes that Damon Runyon plays us to pick the best set of people.” Dr. Green, a a critical role in keeping the most promising biochemist, acknowledges, “The committee scientists engaged in cancer research. “I can’t members’ diverse backgrounds allow them to help but wonder how many of these people, identify the exciting ideas and approaches across along with their potential contributions many disciplines as they emerge to understand toward improving cancer care, would be lost and target cancer.” And new doesn’t always mean without the support of Damon Runyon and better. “Something isn’t good just because it uses its generous donors.”

William G. Kaelin, Jr., MD

• Damon Runyon Board Member and Vice Chair, Scientific Programs, 2016–Present • Chair, Physician-Scientist Training Award Committee, 2015-Present • Member, Clinical Investigator Award Committee, 2006–2016, Chair, 2013–2016 • Dana-Farber Cancer Institute/ Harvard Cancer Center

Rachel Green, PhD

• Chair, Fellowship Award Committee, 2018–present, Member 2015–2018 • Member, Innovation Award Committee, 2008–2014 • Damon Runyon Fellow, 1993–1996 • Johns Hopkins University School of Medicine

2018 ANNUAL REPORT 7 OUR SCIENTISTS Grooming Future Leaders

Mentorship is a critical Every day, researchers pour their energy and passion into work they part of enabling young hope will contribute to lifesaving discoveries, but along the way they will face experimental failures and disappointment. Strong mentors scientists to reach their not only support them through these rough times, but also foster highest potential. the skills needed to have long and successful careers in research.

8 DAMON RUNYON CANCER RESEARCH FOUNDATION Elaine has this exquisite ability, like an oracle, to see where the field is going and navigate in that direction. That isn’t always intuitive. Working with her, you hone that skill.

JULIE SEGRE, Ph D

Damon Runyon Board Member and former to find unconventional solutions to the problems Damon Runyon Fellow Elaine V. Fuchs, PhD, is they were investigating,” says Dr. Segre. exactly the kind of mentor we seek. First and The scientists coming out of the Fuchs lab are foremost, her own career makes her the perfect not only trained in laboratory science, but also role model. She is one of the most renowned the business and infrastructure of running a cell biologists today, highly recognized for lab. They learn how to advocate for themselves, her breakthrough discoveries regarding the have direction and purpose, network, and of the and the role of stem cells communicate their research. “Elaine has this in communicating with immune, dermal, exquisite ability, like an oracle, to see where and other cells in their environment. She is the field is going and navigate in that direction. a Professor at The Rockefeller University, a That isn’t always intuitive. Working with her, Howard Hughes Medical Institute Investigator, you hone that skill,” explains Dr. Segre. and has received numerous prestigious awards for her groundbreaking science. Dr. Segre now mentors many others—including Damon Runyon-Dale F. Frey Breakthrough Beyond her personal success, she has trained Scientist and former Fellow Shruti Naik, PhD. many of the current leaders in science, including They met at the National Institutes of Health seven Damon Runyon scientists. “Developing during Dr. Naik’s graduate studies. Dr. Naik young researchers to be tomorrow’s leaders is went on to work under Dr. Fuchs for her Damon critical to the future of discovery,” says Dr. Fuchs. Runyon Fellowship before launching her own Julie Segre, PhD, currently at the National lab at New York University School of Medicine Human Genome Institute, completed her this year. “My mentors have been my anchors in Damon Runyon Fellowship with Dr. Fuchs. science. Julie, along with my graduate advisor “Elaine fostered a vibrant scientific environment, and Elaine, have been fantastic in leading by where you were challenged to be fearless. She example. They are really daring scientists, who pushed her mentees out of their comfort zones ask big questions,” says Dr. Naik. “Ultimately, the level at which science can advance depends on investing time and Elaine V. Fuchs, PhD effort in emerging leaders,” says Dr. Fuchs.

• Damon Runyon Board Member As a mentor, that requires answering questions, • Damon Runyon Fellow, 1977–1979 probing those failed experiments, and being • Laboratory Head, Laboratory of Mammalian and Development open-minded to new ideas. It also means taking • Rebecca C. Lancefield Professor, the time to understand the individual in the The Rockefeller University lab coat. “By doing this, you empower them to

OPPOSITE PAGE, (L to R): go out into the world and do great things,” adds Shruti Naik, PhD; Elaine V. Fuchs, PhD; Julie Segre, PhD Dr. Naik.

2018 ANNUAL REPORT 9 OUR SCIENTISTS Successful Leadership— Our Ultimate Goal

Jedd D. Wolchok, MD, PhD, a former Damon Runyon Clinical Investigator at Memorial Sloan Damon Runyon has Kettering Cancer Center, is a case in point. He is countless examples a scientist we take great pride in having funded of scientists we long before he became an international leader in immunotherapy*, which has transformed identified and melanoma from deadly to a treatable disease for supported as young people like Karen Taphorn.

scientists who have Karen’s melanoma first appeared in 2011 as a gone on to become bleeding mole on her back. “They surgically leaders in research. removed it, and we hoped that was the end of the journey.” Within a year, melanoma had returned in the scar tissue. Six months after Jedd D. Wolchok, MD, PhD that, a scan revealed the cancer had spread to 24 tumors in her lungs. She was devastated. • Damon Runyon Clinical Investigator, 2003–2008 “When someone gives you a diagnosis of stage • Chief, Melanoma & Immunotherapeutics four melanoma, a thousand things go through Service at MSK • Director, Parker Institute for your mind. You just want to live.” Then she Cancer Immunotherapy at MSK found Dr. Wolchok. Damon Runyon funded Dr. Wolchok at a time when many doubted that immunotherapy, or harnessing patients’ immune systems to attack cancers, would ever work. We believed in Dr. Wolchok and his conviction that immunotherapy would ultimately be successful and enabled him to pursue this lifesaving work. “For the first 20 years of my career, we could expect a person to survive six or seven months, even after treatment with chemotherapy. (Patient survival) has now changed to more than three years, and sometimes indefinitely,” says Dr. Wolchok.

10 DAMON RUNYON CANCER RESEARCH FOUNDATION

348814_DRC_Book_TXT_R4.indd 10 10/29/18 3:06 PM I remember the day that Dr. Wolchok walked in with the scans saying, ‘The tumors are gone!’ I cried, and he said, ‘Why are you crying? You should be happy.’ And he was right.

KAREN TAPHORN

Jedd D. Wolchok, MD, PhD, a former Damon Dr. Wolchok led the Runyon Clinical Investigator at Memorial Sloan clinical trials of the first Kettering Cancer Center, is a case in point. He is immunotherapy approved a scientist we take great pride in having funded by the FDA. He enrolled long before he became an international leader Karen in a more recent in immunotherapy*, which has transformed clinical trial he was melanoma from deadly to a treatable disease for leading that combined people like Karen Taphorn. two immunotherapy KAREN TAPHORN drugs called checkpoint Karen’s melanoma first appeared in 2011 as a inhibitors. The drugs release the natural brakes bleeding mole on her back. “They surgically on immune cells, allowing them to recognize removed it, and we hoped that was the end and attack tumors. The results were astounding. of the journey.” Within a year, melanoma had “Karen went through the entire trial. She had returned in the scar tissue. Six months after no significant side effects and has had a durable that, a scan revealed the cancer had spread to complete remission, which lasts until today.” 24 tumors in her lungs. She was devastated. “When someone gives you a diagnosis of stage Karen maintained her quality of life during four melanoma, a thousand things go through cancer treatment. “The side effects were so your mind. You just want to live.” Then she slight that nobody knew I was sick, period. I did found Dr. Wolchok. not lose my . I did not lose weight. I did not sleep all the time. I carried on my life just as I Damon Runyon funded Dr. Wolchok at a time did before they told me that I was sick. when many doubted that immunotherapy, or harnessing patients’ immune systems “I remember the day that Dr. Wolchok walked to attack cancers, would ever work. We in with the scans saying, ‘The tumors are gone!’ believed in Dr. Wolchok and his conviction that I cried, and he said, ‘Why are you crying? You immunotherapy would ultimately be successful should be happy.’ And he was right.” and enabled him to pursue this lifesaving work. This is what funding future leaders is all about. “For the first 20 years of my career, we could expect a person to survive six or seven months, * This year’s Nobel Prize in Physiology or Medicine recognized immunotherapy as a breakthrough that has led to an entirely new even after treatment with chemotherapy. class of lifesaving drugs. Dr. Wolchok helped bring this treatment to (Patient survival) has now changed to more than patients by conducting the first clinical trial of the first checkpoint three years, and sometimes indefinitely,” says inhibitor approved for cancer. Watch “Anatomy of a Breakthrough,” the story of Dr. Jedd Wolchok’s cutting-edge work in immunotherapy, Dr. Wolchok. at www.damonrunyon.org.

2018 ANNUAL REPORT 11 DAMON RUNYON CANCER RESEARCH FOUNDATION Board of Directors

VICE CHAIR VICE CHAIR Scientific Programs Audit and Secretary William G. Kaelin, Jr., MD Sanford W. Morhouse, Esq. Professor of Medicine Of Counsel Dana-Farber Cancer Institute Schulte Roth & Zabel LLP and Harvard Medical School New York, New York Howard Hughes Medical VICE CHAIR Institute Investigator Board Development Boston, Massachusetts Michael L. Gordon VICE CHAIR Chief Executive Officer Investments and Treasurer and Chief Investment Officer CHAIR Leon G. Cooperman Angelo, Gordon & Company LP Alan M. Leventhal Chairman and Chief New York, New York Chairman and Chief Executive Officer Executive Officer VICE CHAIR Omega Advisors, Inc. Beacon Capital Partners, LLC Development and Marketing New York, New York Boston, Massachusetts David M. Beirne

General Partner X10 Capital San Francisco, California

Steven J. Burakoff, MD Buck French Howard Hughes Medical Dean for Cancer Innovation General Partner Institute Investigator Tisch Cancer Institute X10 Capital Cambridge, Massachusetts Lillian and Henry M. Stratton San Francisco, California Professor of Cancer Medicine Scott Greenstein Icahn School of Medicine at Elaine V. Fuchs, PhD President and Chief Content Officer Mount Sinai Laboratory Head, Laboratory SiriusXM New York, New York of Mammalian Cell Biology New York, New York and Development Deborah J. Coleman Rebecca C. Lancefield Professor Steve Hayden Legal Counsel The Rockefeller University Vice Chairman and Chief Convexity Capital Management LP Howard Hughes Medical Creative Officer (Retired) Boston, Massachusetts Institute Investigator Ogilvy & Mather Worldwide New York, New York New York, New York Robyn Coles President Richard B. Gaynor, MD Jay W. Ireland TRATE Properties, LLC President of Research President and Chief Executive Boston, Massachusetts and Development Officer (Retired) Neon Therapeutics GE Africa Gary E. Erlbaum Cambridge, Massachusetts New York, New York President Greentree Properties Todd R. Golub, MD Morana Jovan-Embiricos, PhD Ardmore, Pennsylvania Chief Scientific Officer and Managing Partner Director, Cancer Program F2 Capital Ventures LLP Thomas J. Fahey, Jr., MD Broad Institute of MIT and Harvard London, United Kingdom Senior Vice President Emeritus Charles A. Dana Investigator in Steven A. Kandarian Memorial Sloan Kettering Human Cancer Genetics Chairman, President and Chief Cancer Center Dana-Farber Cancer Institute Executive Officer New York, New York Professor of Pediatrics MetLife, Inc. Harvard Medical School New York, New York

12 DAMON RUNYON CANCER RESEARCH FOUNDATION Noah Knauf Richard J. O’Reilly, MD Nancy Simonian, MD General Partner Chief, Pediatric Bone Marrow Chief Executive Officer Kleiner Perkins Caufield & Byers Transplant Service Syros Pharmaceuticals, Inc. Menlo Park, California Memorial Sloan Kettering Cambridge, Massachusetts Cancer Center Gabrielle Layton, PhD New York, New York Cynthia Sulzberger Palo Alto, California Wellington, Florida Andrew S. Rachleff David M. Livingston, MD President and Chief Executive Officer Peter Van Camp Deputy Director, Dana-Farber/ Wealthfront Inc. Executive Chairman Harvard Cancer Center Redwood City, California Equinix, Inc. Chief, Charles A. Dana Division of Redwood City, California Human Cancer Genetics William M. Raveis, Jr. Emil Frei Professor of Genetics and Chairman and Chief Executive Officer James A. Wells, PhD Medicine, Harvard Medical School William Raveis Real Estate Professor, Department of Boston, Massachusetts Southport, Connecticut Pharmaceutical Sciences Harry Wm. and Diana V. Hind David G. Marshall Michael V. Seiden, MD, PhD Distinguished Professor Chairman and Chief Executive Officer President and Chief Medical Officer University of California at Amerimar Realty Company The US Oncology Network San Francisco Philadelphia, Pennsylvania McKesson Specialty Health San Francisco, California The Woodlands, Texas John H. Myers Director, Academy Securities Karen D. Seitz Lorraine W. Egan Fairfield, Connecticut Founder and Managing Director President and Chief Executive Officer Fusion Partners Damon Runyon Cancer New York, New York Research Foundation

EMERITUS MEMBERS Connie Lurie Craig B. Thompson, MD Atherton, California President and CEO Sidney Altman, PhD Memorial Sloan Kettering I. George Miller, Jr., MD Professor Emeritus of Molecular, Cancer Center John F. Enders Professor of Pediatrics, Cellular and Developmental New York, New York Biology and Chemistry Prof. of Epidemiology and of Senior Research Scientist of Molecular Biophysics and Virginia Ueberroth Molecular, Cellular and Biochemistry Chairman Developmental Biology Section Chief, Pediatric The Ueberroth Family Foundation Yale University Infectious Diseases Corona del Mar, California New Haven, Connecticut Yale School of Public Health New Haven, Connecticut Robert C. Wright , PhD Senior Advisor Henry C. Pitot, MD, PhD President Emeritus Lee Equity Partners, LLC Professor Emeritus of Oncology, Robert Andrews Millikan New York, New York Pathology and Laboratory Medicine Professor of Biology 522 McArdle Laboratory for California Institute of Technology Robert C. Young, MD Cancer Research Pasadena, California Former Chancellor University of Wisconsin-Madison Fox Chase Cancer Center Kenneth G. Langone School of Medicine and President, RCY Medicine Chairman and Chief Executive Officer Public Health Philadelphia, Pennsylvania Invemed Associates, LLC Madison, Wisconsin New York, New York Katharine F. Plum Ronald Levy, MD Hobe Sound, Florida Robert K. and Helen K. Samuel C. Silverstein, MD Summy Professor John C. Dalton Professor of Stanford University School Physiology and Cellular Biophysics of Medicine Professor of Medicine Stanford, California Columbia University College of Physicians and Surgeons New York, New York

2018 ANNUAL REPORT 13 Bay Area Committee

Carson Eltoukhy Connie Lurie Judy Swanson Atherton, California Atherton, California Hillsborough, California

Buck French Carole Middleton Peter Van Camp General Partner Hillsborough, California Executive Chairman X10 Capital Equinix, Inc. Andrew S. Rachleff San Francisco, California Redwood City, California President and Chief Executive Officer Noah Knauf Wealthfront Inc. James Wells, PhD General Partner Redwood City, California Professor, Department of Kleiner Perkins Caufield & Byers Pharmaceutical Sciences Gordon M. Ringold, PhD Menlo Park, California Harry Wm. and Diana V. Hind Chief Executive Officer Distinguished Professor Gabrielle Layton, PhD Quadriga Biosciences University of California at Palo Alto, California Palo Alto, California San Francisco Brigette Lau Karen D. Seitz San Francisco, California Partner Founder and Managing Director Social Capital LP Fusion Partners Palo Alto, California New York, New York

New York Metro Area Committee

Kathy Braddock Erica Evans Gioffre Karen D. Seitz Managing Director Head of Client Engagement Founder and Managing Director William Raveis Hirtle, Callaghan & Co. Fusion Partners New York, New York West Conshohocken, Pennsylvania New York, New York

Melissa L. Cohn Gerald M. Marshall Executive Vice President of the Co-Chairman and Private Client Group at Chief Executive Officer Family First Funding Amerimar Enterprises, Inc. New York, New York New York, New York

Robyn Coles Joseph R. Osborne, MD, PhD President Chief of Nuclear Medicine and TRATE Properties Molecular Imaging Division Boston, Massachusetts Clinical Chief of Molecular Imaging Innovation Institute (MI3) New York-Presbyterian Hospital/ Weill Cornell Medicine New York, New York

14 DAMON RUNYON CANCER RESEARCH FOUNDATION Award Programs

In FY2018, Damon Runyon awarded nearly $18.3 million to 69 newly selected, exceptional scientists.

DAMON RUNYON-RACHLEFF DAMON RUNYON CLINICAL INNOVATION AWARD INVESTIGATOR AWARD

Supports the next generation of exceptionally creative Supports early career physician-scientists conducting thinkers with high-risk, high-reward ideas that have patient-oriented research. The goal of this innovative the potential to significantly impact our understanding program is to increase the number of physicians capable of and approaches to the prevention, diagnosis or of moving seamlessly between the laboratory and the treatment of cancer. patient’s bedside in search of breakthrough treatments.

TWO-YEAR AWARD: $300,000 THREE-YEAR AWARD: $450,000 with possibility of extension up to an additional $300,000 plus up to $100,000 for medical school loan repayment; with possibility of extension up to an additional $300,000

DAMON RUNYON DAMON RUNYON-SOHN FELLOWSHIP AWARD PEDIATRIC CANCER FELLOWSHIP AWARD Supports the training of the brightest postdoctoral scientists as they embark upon their research careers. This funding Supports dedicated basic scientists and clinicians who enables them to be mentored by established investigators in conduct research with the potential to significantly leading research laboratories across the country. impact the prevention, diagnosis or treatment of one or more pediatric cancers. FOUR-YEAR AWARD: $231,000 FOUR-YEAR AWARD: $231,000

DAMON RUNYON-DALE F. FREY DAMON RUNYON PHYSICIAN- AWARD FOR BREAKTHROUGH SCIENTIST TRAINING AWARD SCIENTISTS Supports and encourages outstanding recent medical Supports a select few Damon Runyon Fellows who have school graduates to pursue cancer research careers by greatly exceeded the Foundation’s highest expectations. providing them with the opportunity for a protected This additional investment in these exceptional research training experience under the mentorship of a individuals catapults their research careers and their highly qualified and gifted mentor. impact on cancer. FOUR-YEAR AWARD: $460,000 TWO-YEAR AWARD: $100,000 plus up to $100,000 for medical school loan repayment

2018 ANNUAL REPORT 15 DAMON RUNYON-RACHLEFF Innovation Award Committee

CHAIR Tarun M. Kapoor, PhD Joshua T. Mendell, MD, PhD Kenneth W. Kinzler, PhD Pels Family Professor Howard Hughes Medical Professor of Oncology Head, Laboratory of Chemistry Institute Investigator Director, Ludwig Center at and Cell Biology Professor and Vice-Chair Johns Hopkins University The Rockefeller University Department of Sidney Kimmel Comprehensive New York, New York University of Texas Southwestern Cancer Center Medical Center Baltimore, Maryland David G. Kirsch, MD, PhD Dallas, Texas Professor and Vice Chair for Basic Benjamin F. Cravatt, PhD and Translational Research Joseph R. Osborne, MD, PhD Professor and Gilula Chair of Department of Radiation Oncology Chief of Nuclear Medicine and Chemical Biology Professor of Pharmacology and Molecular Imaging Division Department of Chemistry Cancer Biology Clinical Chief of Molecular Imaging The Scripps Research Institute Duke University Medical Center Innovation Institute (MI3) La Jolla, California Durham, North Carolina New York-Presbyterian Hospital/ Weill Cornell Medicine Dafna Bar-Sagi, PhD Richard L. Klemke, PhD New York, New York Senior Vice President Professor, Department of Pathology Vice Dean for Science Moores Cancer Center Julie Segre, PhD Chief Scientific Officer University of California, San Diego Senior Investigator Professor, Department of La Jolla, California Chief, Translational and Functional Biochemistry and Molecular Genomics Branch Pharmacology Lewis L. Lanier, PhD Head, Microbial Genomics Section Professor, Department of Medicine American Cancer Society National Human Genome NYU Langone Medical Center Professor and Chair Research Institute, NIH New York, New York Department of Microbiology Bethesda, Maryland and Immunology Abby F. Dernburg, PhD J. Michael Bishop, MD, FOUNDING MEMBER Howard Hughes Medical Distinguished Professor Ronald Levy, MD Institute Investigator University of California, San Francisco Robert K. and Helen K. Professor of Cell and Leader, Cancer Immunology Program Summy Professor Developmental Biology UCSF Helen Diller Family Stanford University School University of California, Berkeley Comprehensive Cancer Center of Medicine Lawrence Berkeley San Francisco, California Stanford, California National Laboratory Berkeley, California

The funding has enabled me to pursue a highly innovative project, which would have been difficult to do without the help from the Foundation. It has allowed me to expand the research of my lab in a new direction.

GUILLEM PRATX, Ph D Damon Runyon-Rachleff Innovator, 2015–2018 Stanford University

16 DAMON RUNYON CANCER RESEARCH FOUNDATION DAMON RUNYON-RACHLEFF Innovation Awards

CALIFORNIA NEW YORK NORTH CAROLINA

Rushika M. Perera, PhD Arnold S. Han, MD, PhD* Lawrence A. David, PhD, Mechanisms of cellular Precision T cell receptor-based and Anthony D. Sung, MD* transformation at the signal organelle cancer therapies at Columbia Personalized prebiotics to optimize level at the University of California, University, New York microbiota metabolism and improve San Francisco transplant outcomes at Duke * Amaia Lujambio, PhD University, Durham MASSACHUSETTS Overcoming the resistance to anti-PD1 immunotherapy in OHIO * Eric S. Fischer, PhD hepatocellular carcinoma at the * Novel mechanisms for small Icahn School of Medicine at Mount Wayne O. Miles, PhD molecule induced targeted Sinai, New York Maximizing pro-apoptotic degradation of RRM family levels at The Ohio State University, at Dana-Farber Cancer Institute, Benjamin L. Martin, PhD, Columbus Boston and David Q. Matus, PhD Cell cycle regulation of cellular *Initial Year Marcela V. Maus, MD, PhD behaviors associated with cancer Next-generation CAR T cells for metastasis at Stony Brook University, EGFRvIII-positive glioblastoma at Stony Brook Massachusetts General Hospital, Boston

DAMON RUNYON-RACHLEFF Innovation Award Stage 2 Funding

CALIFORNIA Roberto Zoncu, PhD* WASHINGTON Identifying and disabling organelle * Brian H. Shirts, MD, PhD Scott J. Dixon, PhD circuits that fuel cancer cell Exploring the role of reductive stress metabolism at the University of Participatory genetics for defining in promoting cancer cell death at California, Berkeley genotype-phenotype associations of Stanford University, Stanford rare cancer variants at the University MARYLAND of Washington, Seattle Nicholas T. Ingolia, PhD Cis-regulatory code for the Christopher M. Jewell, PhD WISCONSIN translational control of gene Harnessing intra-lymph node Philip A. Romero, PhD* expression at the University of controlled release to study and Digital circulating tumor cell California, Berkeley enhance tumor immunity at the detection using scalable molecular University of Maryland, College Park Peter J. Turnbaugh, PhD* logic at the University of Wisconsin, Nadia’s Gift Foundation Innovator OHIO Madison The gut microbiome: an unexpected * contributor to cancer drug resistance Christin E. Burd, PhD *Initial Year at the University of California, San Exploiting mutational specificity to Francisco target RAS-driven melanoma at The Ohio State University, Columbus

2018 ANNUAL REPORT 17 DAMON RUNYON Clinical Investigator Award Committee

CHAIR Howard A. Fine, MD Ramon Parsons, MD, PhD Charles L. Sawyers, MD Director of the Brain Tumor Center Director, Tisch Cancer Institute Chair, Human Oncology and New York-Presbyterian/Weill Icahn Scholar Pathogenesis Program Cornell Medical Center Ward-Coleman Chair Cancer Research The Marie-Josée and Associate Director for Professor and Chairman, Department Henry R. Kravis Chair Translational Research of Oncological Sciences Howard Hughes Medical Sandra and Edward Meyer Icahn School of Medicine at Mount Sinai Institute Investigator Cancer Center New York, New York Memorial Sloan Kettering Feil Professor of Medicine David R. Piwnica-Worms, MD, PhD Cancer Center Chief, Division of Neuro-Oncology New York, New York Department of Neurology Chair and Professor, Department of Weill Cornell Medicine Cancer Systems Imaging Karla V. Ballman, PhD New York, New York Deputy Division Head, Research Chief of the Division of Biostatistics Affairs, Division of Diagnostic Imaging and Epidemiology Amato J. Giaccia, PhD The University of Texas MD Anderson Professor, Department of Healthcare Jack, Lulu and Sam Willson Cancer Center Policy and Research Professor in Cancer Biology Houston, Texas Weill Cornell Medicine Director, Division of Radiation Stanley R. Riddell, MD New York, New York and Cancer Biology Department of Radiation Oncology Full Member, Fred Hutchinson David P. Carbone, MD, PhD Stanford University School of Medicine Cancer Research Center Barbara J. Bonner Chair in Stanford, California Clinical Research Division Lung Cancer Research Program in Immunology Professor, Division of Carl H. June, MD Professor of Medicine and Oncology Internal Medicine Richard W. Vague Professor University of Washington School Director, James Thoracic in Immunotherapy of Medicine Oncology Center Department of Pathology and Seattle, Washington The Ohio State University Laboratory Medicine Kwok-Kin Wong, MD, PhD Comprehensive Cancer Center Perelman School of Medicine Columbus, Ohio Director, Center for Cellular Anne Murnick Cogan and David H. Immunotherapies Cogan Professor of Oncology Nancy E. Davidson, MD Director, Parker Institute for Department of Medicine Senior Vice President, Cancer Immunotherapy Director, Division of Hematology/ Director and Full Member Abramson Cancer Center Medical Oncology Clinical Research Division University of Pennsylvania Laura and Isaac Perlmutter Fred Hutchinson Cancer Philadelphia, Pennsylvania Cancer Center Research Center NYU Langone Health Head, Department of Medicine Andrew L. Kung, MD, PhD New York, New York Division of Medical Oncology Chair, Department of Pediatrics Sandra L. Wong, MD, MS University of Washington Memorial Sloan Kettering Seattle, Washington Cancer Center Chair, Department of Surgery New York, New York Senior Vice President of the S. Gail Eckhardt, MD Surgical Service Line Associate Dean of Cancer Programs Drew M. Pardoll, MD, PhD Dartmouth-Hitchcock Medical Center Director of the LIVESTRONG Director, Bloomberg-Kimmel Institute The Geisel School of Medicine Cancer Institute for Cancer Immunotherapy at Dartmouth Chair, Department of Oncology Co-Director, Cancer Lebanon, New Hampshire Dell Medical School Immunology Program The University of Texas at Austin Sidney Kimmel Comprehensive FOUNDING MEMBER Richard J. O’Reilly, MD Austin, Texas Cancer Center Abeloff Professor in Oncology Chief, Pediatric Bone Marrow Johns Hopkins University School Transplant Service of Medicine Claire L. Tow Chair in Pediatric Baltimore, Maryland Oncology Research Memorial Sloan Kettering Cancer Center

New York, New York

18 DAMON RUNYON CANCER RESEARCH FOUNDATION DAMON RUNYON Clinical Investigator Awards

CALIFORNIA MISSOURI Andrew M. Intlekofer, MD, PhD* Metabolic coupling of the hypoxic Ami S. Bhatt, MD, PhD Vivek K. Arora, MD, PhD niche to stemness with Ross L. Applying microbiome-based Defining a targetable oncogenic dyad Levine, MD, Memorial Sloan therapeutics in cancer patients with in bladder cancer with Lee Ratner, Kettering Cancer Center, New York Linda Boxer, MD, PhD, and Michael MD, PhD, Washington University in P. Snyder, PhD, Stanford University St. Louis Alex Kentsis, MD, PhD School of Medicine, Stanford Richard A. Lumsden Foundation Investigator Gavin P. Dunn, MD, PhD Mechanism and function of * Collin M. Blakely, MD, PhD Characterizing the immunogenic regulatory signaling in acute myeloid Doris Duke-Damon Runyon Clinical Investigator landscape of glioblastoma with leukemia with Scott A. Armstrong, Mechanisms of incomplete John DePersio, MD, PhD, and MD, PhD, and Ross L. Levine, MD, response and primary resistance to Robert Schreiber, PhD, Washington Memorial Sloan Kettering Cancer osimertinib in EGFR-mutant lung University School of Medicine in Center, New York cancer with Trever G. Bivona, MD, St. Louis PhD, University of California, San Christopher A. Klebanoff, MD* Francisco NEW YORK Clinical development of next- generation T cell receptor (TCR)- * Vinod P. Balachandran, MD Catherine C. Smith, MD based adoptive immunotherapies William Raveis Charitable Fund Investigator Defining structure, function and for the treatment of patients with Defining the evolutionary dynamics therapeutic impact of oncogenic FLT3 common epithelial malignancies and antigen potential of neoantigens mutations with Neil P. Shah, MD, with Michel Sadelain, MD, PhD, and for human pancreatic cancer PhD, University of California, San Larry Norton, MD, Memorial Sloan immunotherapy with Steven D. Francisco Kettering Cancer Center, New York Leach, MD, and Jedd D. Wolchok, ILLINOIS MD, PhD, Memorial Sloan Kettering Piro Lito, MD, PhD Cancer Center, New York Jaehyuk Choi, MD, PhD Modeling the evolution of resistance to ERK signaling inhibitors at the Doris Duke-Damon Runyon Clinical Investigator Christopher E. Barbieri, MD, PhD single cell level with Neal X. Rosen, Identification of genetic basis of MetLife Foundation Clinical Investigator altered T cell receptor signaling in Presurgical trials to target distinct MD, PhD, and Charles M. Rudin, cutaneous T cell lymphoma with subclasses of localized prostate MD, PhD, Memorial Sloan Kettering Stephen D. Miller, PhD, and John cancer with Lewis C. Cantley, PhD, Cancer Center, New York D. Crispino, PhD, Northwestern Weill Cornell Medicine, New York Heather L. Yeo, MD University, Chicago Adrienne A. Boire, MD, PhD Use of mobile applications to evaluate MASSACHUSETTS William Raveis Charitable Fund Investigator post surgical recovery in aging Molecular determinants of patients with GI cancer with Manish Geoffrey R. Oxnard, MD leptomeningeal metastasis: a A. Shah, MD, and Deborah Estrin, Gordon Family Clinical Investigator translational approach with Joan PhD, MS, Weill Cornell Medicine, Noninvasive genotyping of cell-free Massagué, PhD, Memorial Sloan New York plasma DNA (cfDNA) as a tool for Kettering Cancer Center, New York guiding personalized lung cancer PENNSYLVANIA care with Pasi Janne, MD, PhD, Dana- Matthew D. Hellmann, MD* Brian C. Capell, MD, PhD* Farber Cancer Institute, Boston Defining intratumoral and peripheral Defining the role of epigenetic mechanisms mediating initiation of enhancer dysfunction in epithelial Mark G. Shrime, MD, PhD response, durability, and resistance carcinogenesis with Shelley L. Berger, Cash transfers for cancer surgery to PD-1 blockade to inform rational PhD, University of Pennsylvania, in West Africa: their health and immunotherapeutic development in Philadelphia economic consequences with NSCLC with Charles M. Rudin, MD, John G. Meara, MD, DMD, MBA, PhD, and Jedd D. Wolchok, MD, PhD, *Initial Year Massachusetts Eye and Ear Infirmary, Memorial Sloan Kettering Cancer Boston Center, New York

2018 ANNUAL REPORT 19 DAMON RUNYON Clinical Investigator Award Continuation Grants

CALIFORNIA Eliezer M. Van Allen, MD* NEW YORK Dissecting response to conventional L. Elizabeth Budde, MD, PhD Joshua Brody, MD and emerging DNA damage and William Raveis Charitable Fund Investigator Targeting CD123 using chimeric repair therapies with Geoffrey I. Flt3L-primed ‘in situ’ vaccination antigen receptor T cells for treatment Shapiro, MD, PhD, Dana-Farber for low-grade lymphoma with Nina of acute myeloid leukemia with Cancer Institute, Boston Stephen J. Forman, MD, FACP, City of Bhardwaj, MD, PhD, and Miriam Hope, Duarte MISSOURI Merad, MD, PhD, Icahn School of Medicine at Mount Sinai, New York MASSACHUSETTS Stephen T. Oh, MD, PhD Targeting aberrant signaling WASHINGTON Priscilla K. Brastianos, MD* pathways in myeloproliferative Aude G. Chapuis, MD* Investigation of novel targeted neoplasms with Daniel Link, MD, Multifaceted transgenic TCR therapeutic approaches for brain Washington University School of approach to high-risk AML with metastases with Keith T. Flaherty, Medicine in St. Louis Philip D. Greenberg, MD, Fred MD, and Tracy T. Batchelor, MD, Hutchinson Cancer Research Center, Massachusetts General Hospital, Seattle Boston

*Initial Award

DAMON RUNYON Fellowship Award Committee

CHAIR Martin D. Burke, PhD, MD Antonio J. Giraldez, PhD Rachel Green, PhD Professor of Chemistry Howard Hughes Medical Howard Hughes Medical University of Illinois at Institute Scholar Institute Investigator Urbana-Champaign Fergus F. Wallace Professor and Bloomberg Distinguished Professor Urbana, Illinois Chair, Department of Genetics Professor of Molecular Biology Yale University School of Medicine and Genetics Jayanta Chaudhuri, PhD New Haven, Connecticut Johns Hopkins University School Professor of Medicine Immunology Program Lucy A. Godley, MD, PhD Baltimore, Maryland Memorial Sloan Kettering Co-Director, Center for Cancer Center Clinical Cancer Genetics VICE CHAIR New York, New York Professor, Department of Medicine Greg Barton, PhD Section of Hematology and Oncology Class of ’36 Endowed Chair, Jennifer Gerton, PhD Cancer Research Center Department of Molecular Investigator The Medicine and Cell Biology Associate Professor, Department Chicago, Illinois Professor of Immunology of Biochemistry and and Pathogenesis Molecular Biology University of California, Berkeley The University of Kansas School Berkeley, California of Medicine Stowers Institute for Medical Research Kansas City, Missouri

20 DAMON RUNYON CANCER RESEARCH FOUNDATION DAMON RUNYON Fellowship Award Committee (continued)

Richard Gregory, PhD Lynne E. Maquat, PhD M. Celeste Simon, PhD Professor J. Lowell Orbison Endowed Chair Scientific Director and Investigator Department of Biological Chemistry and Professor Abramson Family Cancer and Molecular Pharmacology Department of Biochemistry Research Institute Department of Pediatrics and Biophysics Associate Director-Shared Resources, Harvard Medical School School of Medicine and Dentistry Abramson Cancer Center Harvard Institute Director, University of Rochester Arthur H. Rubenstein, The Stem Cell Program at Center for RNA Biology MBBCh Professor Boston Children’s Hospital Chair, University of Rochester Department of Cell and Boston, Massachusetts Graduate Women in Science Developmental Biology University of Rochester University of Pennsylvania Howard C. Hang, PhD Rochester, New York Perelman School of Medicine Richard E. Salomon Family Philadelphia, Pennsylvania Associate Professor Philip A. Newmark, PhD Laboratory of Chemical Biology Howard Hughes Medical Jessica Tyler, PhD and Microbial Pathogenesis Institute Investigator Professor The Rockefeller University Burnell R. Roberts Chair in Department of Pathology New York, New York Regenerative Biology and Laboratory Medicine Morgridge Institute for Research Weill Cornell Medicine E. Jane Albert Hubbard, PhD Department of Zoology New York, New York Professor University of Wisconsin Department of Cell Biology Madison, Wisconsin Matthew G. Vander Heiden, Skirball Institute of MD, PhD Biomolecular Medicine Joel Rothman, PhD Eisen and Chang Career New York University School Professor and Wilcox Family Chair Development Professor of Medicine in Biotechnology Associate Professor of Biology New York, New York University of California, Associate Director, Koch Institute Santa Barbara for Integrative Cancer Research Susan Kaech, PhD Santa Barbara, California at MIT Professor and Director Cambridge, Massachusetts NOMIS Laboratories for David Ruggero, PhD Immunobiology and Professor Amy Wagers, PhD Microbial Studies Helen Diller Family Endowed Chair Forst Family Professor Stem Cell NOMIS Chair in Basic Research and Regenerative Biology Salk Institute for Biological Studies University of California San , Cambridge La Jolla, California Francisco School of Medicine Senior Investigator Member, UCSF Comprehensive Joslin Diabetes Center Jonathan C. Kagan, PhD Cancer Center Harvard Medical School Professor of Pediatrics San Francisco, California Boston, Massachusetts Harvard Medical School Shwachman Chair in Susan R. Schwab, PhD Gastroenterology Associate Professor Boston Children’s Hospital Department of Pathology Boston, Massachusetts Skirball Institute of Biomolecular Medicine New York University School of Medicine New York, New York

2018 ANNUAL REPORT 21 DAMON RUNYON Fellowship Awards

CALIFORNIA Victoria Hung, PhD Kathrin Leppek, PhD Fraternal Order of Eagles Fellow Layton Family Fellow Salk Institute Defining the post-translational Mechanistic characterization of landscape of ribosomes in control 5’UTR RNA elements that confer Corina E. Antal, PhD Robert Black Fellow of gene regulation and cell fate with translational specificity to shape Stromal reprogramming as a Maria Barna, PhD vertebrate embryonic development with Maria Barna, PhD therapeutic approach in pancreatic John C. Janetzko, PhD* cancer with Ronald M. Evans, PhD A biophysical approach to studying Fangfei Qu, PhD* Jeanine L. Van Nostrand, PhD GRK-GPCR complexes with Brian K. Decoding the molecular and cellular Elucidating the AMPK-dependent Kobilka, MD mechanisms of the growth of brain metastases with Julien Sage, PhD regulation of mTOR signaling Chuan Li, PhD* in the metabolic checkpoint of Connie and Bob Lurie Fellow Albert G. Tsai, MD, PhD§ tumorigenesis with Reuben J. Quantifying epistasis between Diagnosis of hematologic malignancies Shaw, PhD tumor suppressor genes and from paucicellular aspirate material Scripps Research Institute revealing the underlying expression using highly multiplexed single cell profiles at the single-cell level in analysis with Sean C. Bendall, PhD Marsha M. Hirschi, PhD* murine lung adenocarcinoma with * Dennis and Marsha Dammerman Fellow Dmitri Petrov, PhD Jing Lin Xie, PhD Molecular engineering of an optically The Mark Foundation for Cancer Research Fellow controlled glutamate receptor with Jianjin Shi, PhD Remembering the past: epigenetic Gabriel C. Lander, PhD Layton Family Fellow mechanisms of cancer drug Biochemical and genetic dissection of resistance with Daniel F. Jarosz, PhD Joseph D. Schonhoft, PhD axon degeneration with Marc Tessier- Merck Fellow Lavigne, PhD University of California, Berkeley Probing the relation between Gina V. Caldas, PhD sequence, aggregation and Shaogeng Steven Tang, PhD Analysis of CSR- function in C. proteotoxicity in cardiac amyloidoses Merck Fellow elegans embryonic cell division with caused by free antibody light chains Toward small-molecule inhibitors Abby F. Dernburg, PhD with Jeffery W. Kelly, PhD against human immune checkpoint PD-1 with Peter S. Kim, PhD Allison Didychuk, PhD* Xiaoyu Zhang, PhD* Viral mimics of host transcription Discovery of chemical probes that Leeat Yankielowicz-Keren, PhD factors in oncogenic herpes viruses support targeted protein degradation Studying the tumor immune with Britt Glaunsinger, PhD in human cancer with Benjamin F. microenvironment in breast cancer using a novel multiplexed imaging Cravatt, PhD Stephanie Gates, PhD* platform with Michael R. Angelo, MD, HHMI Fellow Stanford University PhD, and Edgar G. Engleman, PhD Decoding the ubiquitin receptor Christopher J. Cambier, PhD Stanford University School recognition mechanism of the HHMI Fellow of Medicine 26S proteasome with Andreas In vivo characterization of Martin, PhD mycobacterial cording with Anupam K. Chakravarty, PhD Jamie Lahvic, PhD* Carolyn R. Bertozzi, PhD Investigating the phenomenon of epigenetic inheritance mediated by The Mark Foundation for Cancer Research Fellow Kelsie A. Eichel, PhD* non-amyloid protein aggregates with Uncovering cell non-autonomous Robert A. Swanson Family Fellow Daniel F. Jarosz, PhD mechanisms of tumor suppression Mechanisms of polarized with Iswar Hariharan, MMBS, PhD * membrane protein trafficking Christopher P. Lapointe, PhD Andrew C. Murley, PhD with Kang Shen, PhD Regulatory roles of the 3’ untranslated region in human translation with HHMI Fellow Ryan A. Flynn, MD, PhD Joseph Puglisi, PhD Cell non-autonomous communication The interplay between cellular of ER stress resistance with Andrew G. metabolism and RNA homeostasis in Dillin, PhD disease with Carolyn R. Bertozzi, PhD

22 DAMON RUNYON CANCER RESEARCH FOUNDATION University of California, Los Angeles Trang Nguyen, PhD* CONNECTICUT Bypassing the unresponsiveness of Magdalena E. Potok, PhD Yale School of Medicine T cell anergy and exhaustion with The relationship between epigenetic Arthur Weiss, MD, PhD Zhuobin Liang, PhD gene silencing, nuclear architecture, Mechanistic dissection of the and genome stability with Steven E. Thomas M. Norman, PhD Fanconi anemia pathway in Jacobsen, PhD Identifying the stochastic coordinating R-loop processing and determinants of drug resistance with Christina M. Termini, PhD* DNA repair with Patrick Sung, DPhil, Jonathan S. Weissman, PhD Proteoglycan remodeling of the and Gary Kupfer, MD bone marrow niche regulates Linda T. Vo, PhD* Esen Sefik, PhD* hematopoietic stem cell regeneration Off-the-shelf T cells from human HHMI Fellow with John P. Chute, MD pluripotent stem cells with The effect of microbes, diet on the precise tumor recognition using University of California, San Diego intestinal immune system in the combinatorial antigen-sensing context of obesity with Richard A. circuits with Jeffrey A. Bluestone, PhD Richard W. Baker, PhD Flavell, PhD Understanding the mechanisms Lan Wang, PhD of SWI/SNF-mediated chromatin Seyed Fakhreddin Torabi, PhD Conferring organelle-specificity to remodeling and its misregulation in Robert Black Fellow tail-anchored proteins with Peter cancer with Andres E. Leschziner, Evolution of triplex-forming RNAs Walter, PhD PhD from random sequences: a search for Andrew L. Wolfe, PhD additional MALAT1-like triplex motifs University of California, with Joan A. Steitz, PhD San Francisco The therapeutic potential and biological effects of targeting ILLINOIS Vladislav Belyy, PhD oncogenic KRAS with Frank Mapping the unfolded protein McCormick, PhD The University of Chicago response signaling network with Jiaxi Wu, PhD John D. Leonard, PhD optogenetic actuators with Peter Mechanism of dendritic cell missing- Robert Black Fellow Walter, PhD self recognition and migration to Self-antigen recognition by Kyle G. Daniels, PhD activate CD4 T cell responses with regulatory T cells with Erin J. Adams, Controlling T cell signaling and fate Jason G. Cyster, PhD PhD, and Peter A. Savage, PhD choice using synthetic receptors with Yichen Xu, PhD Sigrid Nachtergaele, PhD Wendell A. Lim, PhD Elucidating the role of ER as a novel The dynamic N1-methyladenosine Qi Hu, PhD RNA-binding protein and its function methylome in eukaryotic mRNA with Design of inhibitors of cancer- in regulating translation with Davide Chuan He, PhD Ruggero, PhD associated mutant GNAS with University of Illinois Kevan M. Shokat, PhD Dian Yang, PhD* Daniel J. Blair, PhD Jeffrey A. Hussmann, PhD Dissecting intratumoral Illini 4000 Fellow Rebecca Ridley Kry Fellow heterogeneity and hierarchy at An automated small molecule Genome-wide measurement of single cell resolution with Jonathan synthesizer for the discovery of new ribosome spacing on individual Weissman, PhD, and Trever G. anti-cancer agents with Martin D. transcripts with Carol A. Gross, PhD Bivona, MD, PhD Burke, MD, PhD

Brian J. Laidlaw, PhD Ziyang Zhang, PhD Sarah Z. Tasker, PhD HHMI Fellow HHMI Fellow HHMI Fellow Role of EBI2 in the regulation of Controlling the activity of bispecific Synthesis and evaluation of a lymphocyte migration during viral T cell engagers with a chemically collection of complex molecules infection and cancer with Jason G. cleavable molecular switch with biased for penetration of the Cyster, PhD Kevan M. Shokat, PhD blood-brain barrier with Paul J. Kara L. McKinley, PhD Xin Zhou, PhD Hergenrother, PhD Mechanisms and functions of Merck Fellow cellular rearrangements in epithelia Engineering “Glue” domains to with Ronald D. Vale, PhD enable cryo-EM study of small cancer protein structures with James A. Lyndsay M. Murrow, PhD Wells, PhD Fate specification of mammary stem cells by cell self-sorting with Zev J. Gartner, PhD

2018 ANNUAL REPORT 23 MARYLAND Yuxiang Zhang, MD, PhD* Harvard Medical School HHMI Fellow Johns Hopkins University Justin A. Bosch, PhD Mechanisms that promote DNA School of Medicine double strand break clusters in brain Characterizing novel molecules and mechanisms that mediate cell- Xintong Dong, PhD and liver with Frederick W. Alt, PhD cell communication with Norbert HHMI Fellow Brigham and Women’s Hospital Perrimon, PhD Investigating ligand-receptor interactions between defensins and Emma V. Watson, PhD Anne E. Dodson, PhD mrgprs in cutaneous inflammation Suzanne and Bob Wright Fellow Transgenerational inheritance of and wound healing with Xinzhong Metabolic stress response: Exploring structure-based infections with Dong, PhD transcript-level regulation of metabolic Scott G. Kennedy, PhD feedback with Stephen J. Elledge, PhD Daniel H. Goldman, PhD Ivana Gasic, PhD Merck Fellow Broad Institute Merck Fellow Elucidating the role of the exon Molecular elucidation of the * junction complex in regulating Matthew Bakalar, PhD interphase microtubule integrity translation of spliced mRNA with Predicting the interactions of T response (MIR) with Timothy Rachel Green, PhD cell receptors with peptide-MHC Mitchison, PhD complexes with Nir Hacohen, PhD Vu Quang Nguyen, PhD Zhejian Ji, PhD* Dana-Farber Cancer Institute Role of chromatin organization in HHMI Fellow Function of the CDc48 ATPase in dynamics of transcription initiation Phillip A. Dumesic, MD, PhD§ with Carl Wu, PhD protein degradation with Tom A. Identification of muscle-secreted Rapoport, PhD Evan J. Worden, PhD factors responsible for local and Lucy Liu, PhD* The mechanistic basis of crosstalk systemic effects of exercise with between histone H2B ubiquitylation Bruce M. Spiegelman, PhD In vivo characterization of muscle and H3K79 methylation with Cynthia autophagy in health and disease with Tikvah K. Hayes, PhD Norbert Perrimon, PhD Wolberger, PhD David M. Livingston, MD, Fellow Nagarajan Nandagopal, PhD* Boris Zinshteyn, PhD Systematic genomic and functional Philip O’Bryan Montgomery, Jr., MD, Fellow HHMI Fellow analysis of small cell lung cancer with Signal integration by bHLH circuits Mechanisms of splicing-independent Matthew L. Meyerson, MD, PhD to enable cell fate decisions with Galit nonsense-mediated mRNA decay * Whitney L. Johnson, PhD Lahav, PhD, and Sean Megason, PhD with Rachel Green, PhD Using organoid cancer models Natasha M. O’Brown, PhD National Institutes of Health to identify genome catastrophe mechanisms with David S. Molecular and cellular mechanisms Danfeng Cai, PhD Pellman, MD of transcytosis regulation in Protein crowding and protein folding blood-brain barrier function with landscapes as predictors of healthy Neil T. Umbreit, PhD Chenghua Gu, PhD Elucidating the mechanism of and diseased cell states with Jennifer Sarah J. Pfau, PhD Lippincott-Schwartz, PhD chromosome bridge resolution with David S. Pellman, MD Investigating the molecular Warakorn Kulalert, PhD* determinants of blood-brain barrier Characterization of the microbiota- Eric S. Wang, PhD heterogeneity with Chenghua Gu, PhD Robert Black Fellow mediated cutaneous neuroimmune Deepshika Ramanan, PhD Enhancing anti-tumor immunity interface and its impacts on National Mah Jongg League Fellow via pharmacological inhibition of tumorigenesis and cancer therapy Identifying functions of regulatory kinases with Nathanael Gray, PhD with Yasmine Belkaid, PhD T cell subsets in intestinal MASSACHUSETTS Harvard T.H. Chan School inflammation and colorectal cancer of Public Health with Christophe Benoist, MD, PhD Boston Children’s Hospital Jeeyun Chung, PhD Justin L. Sparks, PhD Megan L. Insco, MD, PhD§ Unraveling the cellular mechanism Replicative helicase bypass of bulky William Raveis Charitable Fund Fellow of lipid droplet biogenesis with DNA adducts with Johannes C. Investigating transcriptional Tobias C. Walther, PhD, and Robert V. Walter, PhD cyclin dependent kinases as novel Farese Jr., PhD Benjamin M. Stinson, PhD melanoma drug targets with Mechanism of DNA processing Leonard I. Zon, MD during non-homologous end joining

with Johannes C. Walter, PhD, and Joseph L. Loparo, PhD

24 DAMON RUNYON CANCER RESEARCH FOUNDATION Damon Runyon Fellows are incredibly enthusiastic. They are the brightest minds out there, the leaders of the scientific community. They are essentially the key to going forward in science.

AARON F. STRAIGHT, Ph D Damon Runyon Fellowship Award Committee Member, 2018–Present Damon Runyon-Gordon Family Scholar, 2005–2007 Damon Runyon Fellow, 1998–2001 Stanford University School of Medicine

Chuchu Zhang, PhD* Iva Tchasovnikarova, PhD Jose M. Ordovas-Montanes, PhD Molecular dissection of area Deciphering the role of chromatin HHMI Fellow postrema and its role in nausea remodeling in epigenetic repression Single-cell genomic approaches with Stephen Liberles, PhD by the HUSH complex with Robert E. for tracing the contribution of Kingston, PhD inflammation to human colon cancer Harvard University with Alex K. Shalek, PhD Kurt J. Warnhoff, PhD Philip B. Abitua, PhD Molybdenum cofactor biosynthetic Peter M. Westcott, PhD Developmental mechanisms enzymes modulate miRNA biology Exploiting endogenous mutational of killifish cell dispersion and and development with Gary B. processes in cancer to enhance aggregation with Alexander F. Ruvkun, PhD response to immunotherapy with Schier, PhD Tyler E. Jacks, PhD Massachusetts Institute Brian J. Beliveau, PhD of Technology Whitehead Institute for HHMI Fellow Biomedical Research Decoding Polycomb-mediated Alexander M. Jaeger, PhD gene regulation in single cells with HHMI Fellow Laura V. Blanton, PhD single-molecule super resolution Targeting protein folding Lallage Feazel Wall Fellow imaging and synthetic biology with mechanisms to stimulate anti-tumor The impact of sex chromosome Peng Yin, PhD immune responses with Tyler E. constitution on immune cell gene Jacks, PhD expression and function with Monica E. McCallum, PhD David C. Page, MD Understanding alanosine Lindsay M. LaFave, PhD biosynthesis to discover new cancer Investigating epigenetic mechanisms Nora Kory, PhD chemotherapeutics with Emily P. of transformation in SWI/SNF- HHMI Fellow Balskus, PhD mutant non-small cell lung cancer Identifying new components with Tyler E. Jacks, PhD of mitochondrial one-carbon Christopher Wilson, PhD* metabolism with David M. Sabatini, Marion Abbe Fellow Allison N. Lau, PhD MD, PhD Development of a programmable Robert Black Fellow * writer and eraser of m6A RNA Understanding metabolic Daniel H. Lin, PhD methylation with David R. Liu, PhD heterogeneity in pancreatic cancer HHMI Fellow with Matthew G. Vander Heiden, Global influence of mRNA Massachusetts General Hospital MD, PhD conformation on eukaryotic translational regulation with David P. Kai Mao, PhD Evan C. Lien, PhD Bartel, PhD Mechanisms of xenobiotic Impact of diet on tumor metabolism surveillance and regulation with and progression with Matthew G. Benjamin R. Sabari, PhD Gary B. Ruvkun, PhD Vander Heiden, MD, PhD Investigating the role of aberrant genome structuring in T-ALL with Richard A. Young, PhD

2018 ANNUAL REPORT 25 MICHIGAN Cornell University Lacy J. Barton, PhD William Raveis Charitable Fund Fellow University of Michigan Sudeep Banjade, PhD Mechanisms of directed cell migration HHMI Fellow in a complex in vivo environment with Swathi Yadlapalli, PhD Division of labor in ESCRT-III Ruth Lehmann, PhD Neural and genetic basis of metabolic proteins during polymer assembly regulation with Orie T. Shafer, PhD, and membrane remodeling with June-Yong Lee, PhD and Edgar Meyhofer, PhD Scott D. Emr, PhD Investigation of potential roles of serum amyloid A in peripheral MISSOURI Memorial Sloan Kettering Cancer Center Th17 cell pathogenicity with Dan R. Washington University School Littman, MD, PhD of Medicine in St. Louis Harihar Basnet, PhD The Rockefeller University Identifying determinants of latency Darryl A. Wesener, PhD in brain metastatic breast cancer Aleksey Chudnovskiy, PhD* Synthetic food particles for studying cells with Joan Massagué, PhD human gut microbiota function with Defining dendritic cell-T cell interaction history within the tumor Jeffrey I. Gordon, MD Bryan C. King, PhD microenvironment using enzymatic Berger Foundation Fellow NEW JERSEY labeling with Gabriel D. Victora, PhD AMPK-induced catabolism of extracellular proteins: a novel Yusong R. Guo, PhD* survival mechanism for nutrient- HHMI Fellow Andrew A. Bridges, PhD deprived cancer cells with Craig B. Structural and mechanistic HHMI Fellow Thompson, MD characterization of mechanosensitive Bacterial cell fates: The role of Piezo channels with Roderick William Razzell, PhD quorum sensing in biofilm patterning MacKinnon, MD with Bonnie L. Bassler, PhD The role of tension in Hippo pathway signaling with Jennifer A. Zallen, PhD Jonathan R. Whicher, PhD Antony J. Burton, PhD GE Asset Management Fellow Aaron D. Viny, MD§ Sculpting chromatin architecture Structure and mechanism of the William Raveis Charitable Fund Fellow in live cells using protein chemistry voltage-gated potassium channel Role of the Cohesin complex in with Tom W. Muir, PhD hEag1 with Roderick MacKinnon, MD oncogenic transformation of AML NEW YORK with Ross L. Levine, MD Linghe Xi, PhD Dale F. and Betty Ann Frey Fellow Columbia University New York University School of Medicine WNT signaling and fate specification J. Brooks Crickard, PhD of normal versus tumorigenic stem * The Mark Foundation for Cancer Research Fellow Robert S. Banh, PhD cells with Elaine V. Fuchs, PhD Visualizing the strand invasion Merck Fellow Metabolic contribution of sensory during homologous recombination neurons, via peripheral axons, on the single molecule level with to pancreatic tumorigenesis and Eric C. Greene, PhD serine metabolism with Alec Kimmelman, MD, PhD, and Michael Pacold, MD, PhD

The Damon Runyon Fellowship was liberating and enabling for my science, as it provided me with resources to freely test different ideas.

SUNGWOOK WOO, Ph D Damon Runyon Fellow, 2014–2018 Harvard University

26 DAMON RUNYON CANCER RESEARCH FOUNDATION Weill Cornell Medicine Elise C. Jeffery, PhD Ying Qi Shirleen Soh, PhD Characterizing a new hematopoietic Mapping paths and mechanisms of Eric E. Gardner, PharmD, PhD* stem cell niche factor with Sean J. virus-host adaptation with Jesse D. Kenneth G. and Elaine A. Langone Fellow Morrison, PhD Bloom, PhD Interrogating lung adenocarcinoma transformation to small cell lung UTAH Yi Yin, PhD cancer at single cell resolution with Global analysis of DNA break repair University of Utah Harold E. Varmus, MD by single-cell sequencing with Jay A. School of Medicine Shendure, MD, PhD OREGON Alesia N. McKeown, PhD GERMANY Oregon Health and Science University HHMI Fellow Novel roles for retrogenes in host Yunsik Kang, PhD* European Molecular immunity with Nels C. Elde, PhD, and Biology Laboratory Molecular mechanisms regulating Cedric Feschotte, PhD phagocytosis of neurons with Albert Tsai, PhD Marc R. Freeman, PhD WASHINGTON Single-molecule imaging of transcription factors binding PENNSYLVANIA Fred Hutchinson Cancer Research Center dynamics in Drosophila embryos University of Pennsylvania with Justin Crocker, PhD Tera C. Levin, PhD Geoffrey P. Dann, PhD* HHMI Fellow *Initial Year Merck Fellow § Master microbial manipulators: Physician-Scientist Proteomics to bridge protein how hosts are shaped by bacterial arginylation, chromatin, and cancer infections with Harmit S. Malik, PhD with Benjamin A. Garcia, PhD

Romain Riscal, PhD* Jeremy I. Roop, PhD Fructose-1,6 bisphosphatase Fayez Sarofim Fellow Defining virus-host co-evolutionary nuclear localization, new functions dynamics that underlie the unusually and implication in hepatocellular broad HIV neutralizing antibody carcinoma progression with response in infants with Julie M. M. Celeste Simon, PhD Overbaugh, PhD TEXAS Alistair B. Russell, PhD University of Texas Merck Fellow Southwestern Medical Center Impact of heterogeneity on the cellular recognition of influenza Lindsay B. Case, PhD infection with Jesse D. Bloom, PhD Robert Black Fellow Regulation of integrin clustering on supported lipid bilayers with Michael Rosen, PhD

Damon Runyon selects and supports some of the most driven research in the scientific community, but inspiration alone cannot drive progress. As with all human endeavors, practical support is essential.

BRITTANY ADAMSON, PhD Damon Runyon Fellow, 2014–2017 University of California, San Francisco

2018 ANNUAL REPORT 27 DAMON RUNYON-SOHN Pediatric Cancer Fellowship Award Committee

CHAIR Peter D. Cole, MD Martine F. Roussel, PhD Andrew L. Kung, MD, PhD Professor of Pediatrics Member and Endowed Chair Chair, Department of Pediatrics Chief, Division of Pediatric in Molecular Oncogenesis Memorial Sloan Kettering Hematology/Oncology Co-Leader, Cancer Biology Program Cancer Center Embrace Kids Foundation Chair St. Jude Children’s Research Hospital New York, New York in Pediatric Hematology/Oncology Professor, Department of Rutgers Cancer Institute Molecule Sciences Scott A. Armstrong, MD, PhD of New Jersey The University of Tennessee Chair, Department of Robert Wood Johnson Medical School Health Science Center Pediatric Oncology Rutgers, The State University Memphis, Tennessee Dana-Farber Cancer Institute of New Jersey David G. Nathan Professor of New Brunswick, New Jersey Agata Smogorzewska, MD, PhD Pediatrics, Harvard Medical School Associate Professor Associate Chief of the Division of Adolfo A. Ferrando, MD, PhD Head, Laboratory of Hematology/Oncology at Professor of Pediatrics and Pathology Genome Maintenance Boston Children’s Hospital Director, WOLF Foundation The Rockefeller University Boston, Massachusetts Leukemia/Lymphoma Laboratory New York, New York Institute for Cancer Genetics Patrick A. Brown, MD Columbia University Medical Center Director, Pediatric Leukemia Program New York, New York Associate Professor, Department of Oncology James M. Olson, MD, PhD Johns Hopkins University Member School of Medicine Division of Clinical Research Baltimore, Maryland Fred Hutchinson Cancer Research Center Professor of Pediatric Hematology/Oncology University of Washington School of Medicine Seattle, Washington

The Damon Runyon-Sohn award was a vital resource for me as an early career scientist with the goal of making an impact in the treatment of pediatric cancer. I was afforded time to explore the biology of these malignancies and make discoveries that will benefit the lives of patients.

MARK W. ZIMMERMAN, Ph D Damon Runyon-Sohn Pediatric Fellow, 2014–2018 Damon Runyon-Jake Wetchler Awardee, 2016 Dana-Farber Cancer Institute

28 DAMON RUNYON CANCER RESEARCH FOUNDATION DAMON RUNYON-SOHN Pediatric Cancer Fellowship Awards

CALIFORNIA Cara A. Rabik, MD, PhD§ NEW YORK Determination of the role of WT1 in Özlem Aksoy, PhD hematopoiesis and leukemogenesis Robert L. Bowman, PhD Understanding the role of with Patrick A. Brown, MD, Johns Interrogating the subclonal translational control in humanized Hopkins University, Baltimore architecture and functional mouse models for medulloblastoma contributions of mutation order in with Davide Ruggero, PhD, University MASSACHUSETTS FLT3-ITD mutant AML with of California, San Francisco Ross L. Levine, MD, Memorial Sloan Adam D. Durbin, MD* Kettering Cancer Center, New York Zhipeng Lu, PhD Interrogation of neuroblastoma * Layton Family Fellow of the Damon Runyon- dependencies and non-coding Srinjoy Chakraborti, PhD Sohn Pediatric Cancer Fellowship Award RNAs on the core-regulatory circuitry Mining pHLA and T cell receptor Elucidating the role of dynamic RNA for therapeutic inhibition with (TCR) specificities by phage display structures in cancer with Howard Y. A. Thomas Look, MD, Dana-Farber for de novo TCR engineering and Chang, MD, PhD, Stanford University Cancer Institute, Boston personalized cancer therapy with School of Medicine, Stanford Jonathan R. Lai, PhD, Albert Einstein Amanda Balboni Iniguez, PhD College of Medicine, Bronx Kathryn R. Taylor, PhD Targeting the EWS-FLI oncoprotein The effect of neuronal activity on in Ewing sarcoma with CDK12/13 Marissa Rashkovan, PhD pediatric glioma invasion with inhibitors with Kimberly Stegmaier, Targeting metabolic vulnerabilities Michelle L. Monje, MD, PhD, MD, Dana-Farber Cancer Institute, in ETP-ALL with Adolfo A. Ferrando, Stanford University School of Boston MD, PhD, Columbia University Medicine, Stanford Medical Center, New York Sarah N. Olsen, PhD* MARYLAND Targeted degradation of the MLL-AF9 Yadira M. Soto-Feliciano, PhD Dissecting the role of Menin in acute Stacy L. Cooper, MD§ fusion oncoprotein in acute myeloid leukemia with C. David Allis, PhD, The Cebpa +37kb enhancer is a leukemia with Scott A. Armstrong, The Rockefeller University, New York critical target of transformation in MD, PhD, Dana-Farber Cancer acute myeloid leukemia with Institute, Boston WASHINGTON Alan D. Friedman, MD, Johns Maxim Pimkin, MD, PhD*§ Hopkins University, Baltimore Jay F. Sarthy, MD, PhD*§ Divergent core transcriptional Characterization of the epigenomic § circuitries highlight context-specific Michael A. Koldobskiy, MD, PhD landscape of diffuse midline gliomas vulnerabilities in AML with Stuart DNA methylation stochasticity with Steven Henikoff, PhD, Fred Orkin, MD, Harvard Medical School, in pediatric pre-B cell acute Hutchinson Cancer Research Center, Boston lymphoblastic leukemia with Seattle Andrew P. Feinberg, MD, Johns MICHIGAN Hopkins University, Baltimore Challice L. Bonifant, MD, PhD§

Dual-antigen targeting by ENG-T

cells as improved anti-AML therapy

with Pavan Reddy, MD, University of

Michigan, Ann Arbor

2018 ANNUAL REPORT 29 DAMON RUNYON-DALE F. FREY AWARD for Breakthrough Scientists

Ryan D. Baldridge, PhD* Chao Lu, PhD* Shruti Naik, PhD* Investigating the mechanism of Giannandrea Family Breakthrough Scientist Marilyn and Scott Urdang retro-translocation by ERAD at the Chromatin dysregulation as driver of Breakthrough Scientist University of Michigan, Ann Arbor, oncogenesis at Columbia University, Immune-epidermal stem cell Michigan New York, New York crosstalk in skin inflammation at New York University School of * Liron Bar-Peled, PhD* Matthew P. Miller, PhD Medicine, New York, New York Identification of cysteine liabilities Deciphering tension-dependent * in NRF2-driven cancers at stabilization of kinetochore- Neel H. Shah, PhD Massachusetts General Hospital, microtubule interactions at the Identifying divergent mechanisms Boston, Massachusetts University of Utah, Salt Lake City, Utah of oncogenicity in tyrosine kinases at Columbia University, New York,

New York

*Initial Year

DAMON RUNYON Physician-Scientist Training Award Committee

CHAIR Lucy A. Godley, MD, PhD Kornelia Polyak, MD, PhD William G. Kaelin, Jr., MD Co-Director, Center for Professor of Medicine Professor of Medicine Clinical Cancer Genetics Department of Medical Oncology Dana-Farber Cancer Institute Professor, Department of Medicine Dana-Farber Cancer Institute and Harvard Medical School Section of Hematology and Oncology Harvard Medical School Howard Hughes Medical Cancer Research Center Boston, Massachusetts Institute Investigator The University of Chicago Medicine Boston, Massachusetts Chicago, Illinois Jeremy N. Rich, MD Professor of Medicine David P. Carbone, MD, PhD Peter S. Nelson, MD Director, Neuro-Oncology Barbara J. Bonner Chair in Member, Division of Human Biology Director, Brain Tumor Institute Lung Cancer Research Endowed Chair for Prostate University of California, San Diego Director, Thoracic Oncology Center Cancer Research La Jolla, California Professor, Division of Fred Hutchinson Cancer Medical Oncology Research Center Cassian Yee, MD Comprehensive Cancer Center Professor, Division of Professor, Department of The Ohio State University Medical Oncology Melanoma Medical Oncology Columbus, Ohio Adjunct Professor, Genomic Professor, Department of Immunology Sciences and Pathology Division of Cancer Medicine University of Washington School Director, Solid Tumor Cell Therapy of Medicine Center for Cancer Seattle, Washington Immunology Research The University of Texas MD Anderson Cancer Center Houston, Texas

30 DAMON RUNYON CANCER RESEARCH FOUNDATION DAMON RUNYON Physician-Scientist Training Awards

Pavan Bachireddy, MD Michael W. Drazer, MD Loretta S. Li, MD Coevolution of tumor and T Defining leukomogenic mechanisms Mechanisms of disease and cell heterogeneity following in hereditary hematologic resistance in CRLF2-rearranged immunotherapy with malignancies with Lucy A. Godley, B-cell acute lymphoblastic leukemia Catherine J. Wu, MD, Dana- MD, PhD, The University of Chicago with David M. Weinstock, MD, Dana- Farber Cancer Institute, Boston, Medicine, Chicago, Illinois Farber Cancer Institute, Boston, Massachusetts Massachusetts John R. Ferrarone, MD* Giada Bianchi, MD, PhD Lee Cooperman Physician-Scientist David Liu, MD* Damon Runyon-Celgene Physician-Scientist Seeking and evaluating novel Dissecting differential therapy Molecular mechanisms of ROBO1 in therapeutic targets in human lung response in melanoma through multiple myeloma pathogenesis with adenocarcinomas with loss-of- clinical computational oncology with Kenneth C. Anderson, MD, Dana- function mutations in LKB1 with Eliezer M. Van Allen, MD, and Keith T. Farber Cancer Institute, Boston, Harold E. Varmus, MD, Weill Cornell Flaherty, MD, Dana-Farber Cancer Massachusetts Medicine, New York, New York Institute, Boston, Massachusetts

Kristopher R. Bosse, MD Christopher J. Gibson, MD Harshabad Singh, MBBS* GPC2 as an oncogene and Elucidating the connection between Cellular origins of Barrett’s immunotherapeutic target in high- clonal hematopoiesis and lymphoma esophagus and its role in risk neuroblastoma with John M. in humans with Benjamin L. Ebert, development of adenocarcinoma Maris, MD, Children’s Hospital MD, PhD, Dana-Farber Cancer with Ramesh A. Shivdasani, MD, of Philadelphia, Philadelphia, Institute, Boston, Massachusetts PhD, Dana-Farber Cancer Institute, Pennsylvania Boston, Massachusetts Lillian M. Guenther, MD* Julia C. Carnevale, MD Investigation of CITED2 as a novel Melody Smith, MD Developing new therapeutic dependency in Ewing sarcoma with CD19 targeted donor T cells improve approaches for pancreatic cancer Kimberly Stegmaier, MD, Dana- graft versus tumor activity and with homologous recombination Farber Cancer Institute, Boston, reduce graft versus host disease with repair defects with Alan Ashworth, Massachusetts Marcel R.M. van den Brink, MD, PhD, PhD, University of California, San Memorial Sloan Kettering Cancer Carolyn C. Jackson, MD, MPH Francisco, California Center, New York, New York Genetic dissection of pediatric classic Jennifer L. Caswell-Jin, MD Kaposi sarcoma with Jean-Laurent Sakiko Suzuki, MD Breast cancer evolution and Casanova, MD, PhD, Memorial Sloan AON-directed alternative splicing resistance in response to HER2- Kettering Cancer Center, New York, as a novel therapy for leukemia targeted therapy with Christina N. New York with Michelle A. Kelliher, PhD, and Curtis, PhD, and Allison W. Kurian, Peter E. Newburger, MD, University David M. Kurtz, MD, PhD MD, MSc, Stanford University, of Massachusetts Medical School, Response prediction and Stanford, California Worcester, Massachusetts personalized therapy from Nicholas C. DeVito, MD* mathematical modeling of circulating * Initial Year Investigating the role of EMT- tumor DNA in non-Hodgkin mediated dendritic cell tolerization lymphoma with Arash Ash Alizadeh, in checkpoint inhibitor resistance MD, PhD, Stanford University School with Brent A. Hanks, MD, PhD, Duke of Medicine, Stanford, California University, Durham, North Carolina

2018 ANNUAL REPORT 31 Thank You to Our Donors

Your support this year enabled us to invest nearly $18.3 million in the next generation of leading cancer researchers exploring bold new ideas. Since our founding in 1946, in partnership with donors across the nation, Damon Runyon has invested close to $355 million and funded nearly 3,700 young scientists.

DONOR SPOTLIGHT

The $1 million Connie and Robert Lurie Breakthrough Challenge Fund was established to mark Damon Runyon’s upcoming 75th Anniversary in 2021, and to generate new support for Damon Runyon scientists working at Stanford University, the Gladstone Institute, and the Universities of BOB AND CONNIE LURIE California at San Francisco, Berkeley and Santa Cruz. Our heartfelt thanks go to the Lurie Family for generations of “We hope the Challenge Fund will encourage new support by people support, beginning with Louis “Lou” Lurie, then his son who don’t know about the work of the Robert “Bob” Lurie and his wife Connie, who have been Foundation and inspire them to get involved. Our goal is to put Damon extremely generous to Damon Runyon, supporting 14 Damon Runyon on the map as a critically Runyon scientists and introducing countless people to our important supporter of the best young scientists in the Bay Area.” important work. — Connie Lurie

AWARD SPONSORS

We are grateful to our individual, foundation, and corporate sponsors who have partnered with us to launch new programs or are funding one or more of our scientists. Donors can choose to fund scientists based on location, institution, research focus, or cancer type, and the award can For more information, BRYAN C. KING, PhD, be named in recognition of their gift. Berger Foundation Fellow, go to: www.damonrunyon.org/get-involved/sponsor. with RENEE BERGER at the Breakthroughs by the Beach AWARD SPONSORS ARE LISTED ON PAGES 34–36. event in Sag Harbor

32 DAMON RUNYON CANCER RESEARCH FOUNDATION Events & Broadway Tickets

2018 ANNUAL BREAKFAST RUNYON 5K AT YANKEE STADIUM

Our 2018 Annual Breakfast raised a record- In April 2018, the tenth annual Damon Runyon 5K breaking $2.6 million. Board Member Leon G. at Yankee Stadium drew nearly 2,300 participants Cooperman, Founder, Chairman and CEO and raised more than $420,000. The event was of Omega Advisors, Inc., was honored and presented by MetLife Foundation, with additional introduced by Damon Runyon Emeritus Board support from Poland Spring, RXBAR, Utz, Cabot, member Kenneth G. Langone, Chairman and 24 Hour Fitness, New York Post, SiriusXM and CEO of Invemed Associates, LLC. the New York Yankees.

RAVEIS RIDE + WALK BROADWAY TICKETS

The William Raveis Charitable Fund hosted Damon Runyon Broadway Tickets offers premium the third annual Raveis Ride + Walk in October seats to all of Broadway’s hit shows. We are 2017, raising more than $500,000 for Damon grateful to the Shubert Organization, Nederlander Runyon scientists. We are grateful to everyone Productions, Jujamcyn Theaters, and Disney at William Raveis for their partnership and Theatrical Productions for making this program support in raising more than $1.5 million for possible. Special thanks to our Premier Circle Damon Runyon over three years! members for their ongoing support of our efforts to end cancer. To purchase tickets or gift certificates please visit www.damonrunyon.org/broadway.

2018 ANNUAL REPORT 33 Sponsored Awards

We are fortunate to have individual, foundation, and corporate sponsors who have partnered with us to launch or provide continuing support for specific award programs. We sincerely thank them for their vision.

DAMON RUNYON-RACHLEFF CLINICAL INVESTIGATOR Fraternal Order of Eagles Fellow* INNOVATION AWARDS CONTINUATION GRANT Victoria Hung, PhD Stanford University This award was established thanks to Follow-up funding for select the vision and generosity of Debbie Clinical Investigators has been GE Asset Management Fellow and Andy Rachleff. provided thanks to the William K. Jonathan R. Whicher, PhD Bowes, Jr. Foundation. The Rockefeller University Nadia’s Gift Foundation Innovator Peter J. Turnbaugh, PhD Howard Hughes Medical Institute William Raveis Charitable Foundation (HHMI) Fellows University of California, Clinical Investigator Sudeep Banjade, PhD San Francisco Joshua Brody, MD Cornell University Icahn School of Medicine at CLINICAL INVESTIGATOR AWARDS Mount Sinai Brian J. Beliveau, PhD FELLOWSHIP AWARDS Harvard University This award was initially established Andrew A. Bridges, PhD in partnership with Eli Lilly and The following awards are funded Princeton University Company. In addition to the named by donors who have generously awards, it is supported by Accelerating endowed an award in perpetuity or Christopher J. Cambier, PhD Cancer Cures, a collaboration sponsored an individual Fellow. Stanford University between Damon Runyon and leading biopharmaceutical companies. Berger Foundation Fellow Xintong Dong, PhD Bryan C. King, PhD Johns Hopkins University Gordon Family Clinical Investigator Memorial Sloan Kettering School of Medicine Geoffrey R. Oxnard, MD Cancer Center Dana-Farber Cancer Institute Stephanie Gates, PhD Connie and Bob Lurie Fellow* University of California, Berkeley MetLife Foundation Clinical Investigator Chuan Li, PhD Christopher E. Barbieri, MD, PhD Stanford University Yusong R. Guo, PhD Weill Cornell Medicine The Rockefeller University Dale F. and Betty Ann Frey Fellow* Richard A. Lumsden Foundation Linghe Xi, PhD Alexander M. Jaeger, PhD Clinical Investigator The Rockefeller University Alex Kentsis, MD, PhD Massachusetts Institute of Technology Memorial Sloan Kettering David M. Livingston, MD, Fellow Zhejian Ji, PhD Cancer Center Tikvah K. Hayes, PhD Harvard Medical School Dana-Farber Cancer Institute William Raveis Charitable Foundation Nora Kory, PhD Clinical Investigators Dennis and Marsha Dammerman Fellow* Whitehead Institute for Vinod P. Balachandran, MD Marsha M. Hirschi, PhD Biomedical Research Memorial Sloan Kettering Scripps Research Institute Cancer Center Brian J. Laidlaw, PhD Fayez Sarofim Fellow* Adrienne A. Boire, MD, PhD Jeremy I. Roop, PhD University of California, San Francisco Memorial Sloan Kettering Fred Hutchinson Cancer Cancer Center Research Center

34 DAMON RUNYON CANCER RESEARCH FOUNDATION Daniel H. Lin, PhD Merck Fellows William Raveis Charitable Fund Fellows Whitehead Institute for Robert S. Banh, PhD Lacy J. Barton, PhD Biomedical Research New York University School New York University of Medicine School of Medicine Alesia N. McKeown, PhD University of Utah School of Medicine Geoffrey P. Dann, PhD Megan L. Insco, MD, PhD University of Pennsylvania Boston Children’s Hospital Andrew C. Murley, PhD University of California, Berkeley Ivana Gasic, PhD Aaron D. Viny, MD Harvard Medical School Memorial Sloan Kettering Jose M. Ordovas-Montanes, PhD Cancer Center Daniel H. Goldman, PhD Massachusetts Institute DAMON RUNYON-DALE F. of Technology Johns Hopkins University School of Medicine FREY AWARD FOR BREAKTHROUGH SCIENTISTS Esen Sefik, PhD Alistair B. Russell, PhD Yale School of Medicine Fred Hutchinson Cancer Giannandrea Family Breakthrough Scientist Chao Lu, PhD Sarah Z. Tasker, PhD Research Center Columbia University University of Illinois Joseph D. Schonhoft, PhD Marilyn and Scott Urdang Scripps Research Institute Yuxiang Zhang, MD, PhD Breakthrough Scientist Boston Children’s Hospital Shaogeng Steven Tang, PhD Shruti Naik, PhD New York University School Ziyang Zhang, PhD Stanford University of Medicine University of California, San Francisco Xin Zhou, PhD DAMON RUNYON-SOHN University of California, San Francisco Boris Zinshteyn, PhD PEDIATRIC CANCER Johns Hopkins University National Mah Jongg League Fellow FELLOWSHIP AWARD School of Medicine Deepshika Ramanan, PhD This award program was Harvard Medical School Illini 4000 Fellow launched in partnership with the Daniel J. Blair, PhD Philip O’Bryan Montgomery, Jr., MD, Fellow generous support of the Sohn University of Illinois Nagarajan Nandagopal, PhD Conference Foundation. Harvard Medical School Kenneth G. and Elaine A. Langone Fellow* Damon Runyon-Sohn Pediatric Eric E. Gardner, PharmD, PhD Rebecca Ridley Kry Fellow* Cancer Fellows supported by the Weill Cornell Medicine Jeffrey A. Hussmann, PhD Sohn Conference Foundation University of California, San Francisco Lallage Feazel Wall Fellow* Özlem Aksoy, PhD Laura V. Blanton, PhD Robert A. Swanson Family Fellow University of California, San Francisco Whitehead Institute for Kelsie A. Eichel, PhD Biomedical Research Stanford University Amanda Balboni Iniguez, PhD Dana-Farber Cancer Institute Layton Family Fellows Robert Black Fellows Kathrin Leppek, PhD Corina E. Antal, PhD Challice L. Bonifant, MD, PhD Stanford University School of Medicine Salk Institute University of Michigan

Jianjin Shi, PhD Lindsay B. Case, PhD Stacy L. Cooper, MD Stanford University University of Texas Southwestern Johns Hopkins University Medical Center Marion Abbe Fellow* Adam D. Durbin, MD, PhD Christopher Wilson, PhD Allison N. Lau, PhD Dana-Farber Cancer Institute Harvard University Massachusetts Institute of Technology Michael A. Koldobskiy, MD, PhD The Mark Foundation for Cancer John D. Leonard, PhD Johns Hopkins University Research Fellows The University of Chicago Cara A. Rabik, MD, PhD J. Brooks Crickard, PhD Seyed F. Torabi, PhD Johns Hopkins University Columbia University Yale School of Medicine Marissa Rashkovan, PhD Jamie Lahvic, PhD Eric S. Wang, PhD Columbia-Presbyterian University of California, Berkeley Dana-Farber Cancer Institute Medical Center Jing Lin Xie, PhD Suzanne and Bob Wright Fellow* Jay F. Sarthy, MD, PhD Stanford University School of Medicine Emma V. Watson, PhD Fred Hutchinson Cancer Brigham and Women’s Hospital Research Center

2018 ANNUAL REPORT 35 Kathryn R. Taylor, PhD DAMON RUNYON PHYSICIAN- DAMON RUNYON-JAKE Stanford University School of Medicine SCIENTIST TRAINING AWARDS WETCHLER AWARD FOR PEDIATRIC INNOVATION Layton Family Fellow of the This award was established thanks Damon Runyon-Sohn Pediatric to the generosity of Damon Runyon This $5,000 award is named in honor Cancer Fellowship Board Members Leon G. Cooperman of Jake Wetchler, who died at age Zhipeng Lu, PhD and Michael L. Gordon. 20 after a heroic fight against two Stanford University School of Medicine different cancers. Damon Runyon-Celgene Physician-Scientist Giada Bianchi, MD Amanda Balboni Iniguez, PhD Dana-Farber Cancer Institute Dana-Farber Cancer Institute

Lee Cooperman Physician-Scientist *In perpetuity John R. Ferrarone, MD Weill Cornell Medicine

Accelerating Cancer Cures

Thank you to Eli Lilly and Company, Celgene, Genentech, Gilead, Merck, and Novartis for partnering with us to support the Damon Runyon Clinical Investigator Award and for helping foster communication and collaboration between our scientists and the biopharmaceutical industry.

36 DAMON RUNYON CANCER RESEARCH FOUNDATION Our Contributors

The Damon Runyon Cancer Research Foundation acknowledges the generosity of the many donors who supported our brilliant researchers through gifts to the Foundation from July 1, 2017 to June 30, 2018. Those whose individual lifetime giving is $100,000 or more are in bold, and those whose lifetime giving exceeds $1 million are in blue. We are especially grateful to these extraordinarily generous and committed donors.

$1,000,000+ Schwab Charitable Paul Montrone and Perspecta Trust Anonymous Judy C. Swanson Mary and Eugene F. Murphy William K. Bowes, Jr. Foundation U.S. Trust Company of New York The New York Community Trust Estate of Myra Cohen Estate of Winifred Wiederkerr Estate of Selina L. Purcell The Leon and Toby Cooperman The Frances and Abraham Family Foundation $50,000 – $99,999 Reichman Charitable Trust Angelo, Gordon & Co. The Bruce Robert Reid $500,000 – $999,999 Terry and David Beirne Family Foundation Michael L. Gordon Deborah J. Coleman and Karen D. Seitz The Mark Foundation Timothy W. Diggins Cynthia F. Sulzberger for Cancer Research Community Foundation and Steven B. Green Merck & Company, Inc. for Monterey County Textor Family Foundation William Raveis Charitable Fund Hettinger Foundation Sohn Conference Foundation MetLife $10,000 – $24,999 Louis and Rachel Rudin Anonymous $100,000 – $499,999 Foundation, Inc. Arbor Realty Trust American Endowment Foundation Select Equity Group Foundation Barthold Family Foundation The Bakewell Foundation Silicon Valley Community Baupost Group, LLC Sol and Margaret Berger Foundation Nancy and Larry Bossidy Foundation Anita Tarr Turk Fund for Breast BTIG, LLC Robert Black Charitable Cancer Research Charles Schwab & Co Foundation The Varelas Family Fund Estate of Irene H. Cohn The Carefree Foundation James J. Combs Estate of Adrienne and $25,000 – $49,999 Echlin Foundation Harry Chamberlain American Media Lorraine and Bill Egan Estate of Alice E. Conover Anonymous Edward P. Evans Foundation Emanuel J. Friedman Appaloosa L.P. Fiduciary Trust International Philanthropies BasePoint The Fine and Greenwald Fidelity Investments Charitable Beacon Capital Partners, LLC Foundation, Inc. Gift Fund Robyn and Tony Coles, MD Betty Ann Frey Samuel Freeman Charitable Trust Fiona and Stanley Druckenmiller Glover Acquisitions LLC Genentech, Inc. Shelley and Steven Einhorn Paula and James Gould The Giannandrea Family Fund Estate of Rita Eisenberg Joan Lobis Brown Estate of Mary A. Higgs Erlbaum Family Foundation and Jeremy Grayzel Howard Hughes Medical Institute F2 Ventures Sharon and Scott Greenstein The Layton Family Fund Goldman Sachs Steve Hayden Sherry and Alan Leventhal Grand Aerie Fraternal Order Estate of Irma T. Hirschl Family Foundation of Eagles Andre Hunter Eli Lilly and Company Illini 4000 Caroline and Ed Hyman Richard A. Lumsden Foundation Independent Charities of America Valerie and Jay Ireland MetLife Foundation Elaine and Kenneth Langone Iridian Asset Management LLC Nadia’s Gift Foundation Sandy and David Marshall Jewish Communal Fund National Mah Jongg John McKeown Jewish Community Federation League Foundation Gordon H. and Karen M. Millner Steven A. Kandarian Debbie and Andy Rachleff Family Foundation Mel Karmazin

* Our donor lists are checked carefully. However, if you have any corrections or questions, please call us at 877.722.6237. The full pledge amount is listed in the year the pledge is made. In subsequent years, pledge payments are listed.

2018 ANNUAL REPORT 37 OUR CONTRIBUTORS (CONTINUED)

Angela and Noah Knauf Alyce and Philip DeToledo Nancy Simonian, MD Brigette Lau and Helga and Frank Doyle Robie and John Spector Chamath Palihapitiya Jane and Larry Droppa Patricia and James Staley The Lichtenberger Foundation Cheryl and Blair Effron Stewart Senter, Inc. Anthony F. LoFrisco Ensemble Capital LLC Barbara and Peter Strauss Lonsdale Family Philanthropic Fund Estate of Edward and Philanthropic Fund Katherine and Henry Mannix III Bozena Etnyre Suhler Family Fund McKesson Corporation Fairfield County’s Community Jennifer Toll Paul, Weiss, Rifkind, Wharton Foundation Jennifer and Don Torey & Garrison LLP The Frances and Jeffrey Fisher The Turk Family Foundation Pyramid Hotel Group Charitable Foundation UBS Donor Advised Fund The Raiff Foundation Linda Frankel Lief Sannen and Lawrence Wieman Rebecca and Arthur Samberg Kelly and Buck French Estate of Carl J. Wilson Gary M. Saretsky Friedman Family Foundation Roy J. Zuckerberg Family Foundation Schulte Roth & Zabel LLP Gabelli Funds Paula Ryan, MD, PhD, and Erica Evans Gioffre and $1,000 – $4,999 Michael Seiden, MD, PhD Michael Gioffre Kara and Jon Aborn Henry J. and Kathleen Singer The Walter F. and Alice Girham Steven I. Abrams Family Foundation Foundation, Inc. William J. Alexander The Richard C. and Theresa P. Mignon Groch Carolyn Aller Smith Memorial Fund Heitman LLC Sharman and David Altshuler State Street Global Advisors Donald Herdrich Advised Fund The Symonds Foundation Joan and Robert Hess Dean V. Ambrose Carol and Lee Tesconi Lisa Gross and Richard Hoffman America’s Best Charities Tzedakah Foundation Sandra Horbach and America’s Charities Laura and Peter Van Camp Steven Skoler Mary and Roy Anderson Vanguard Charitable Lori and Wayne Hummel Charitable Foundation Volpi-Cupal Family Fund Interco Charitable Trust Anonymous The Jake Wetchler Foundation JANA Partners LLC Ashner Family Evergreen Foundation Peter J. Worth Jewish Community Foundation Wendy Askew Julia J. Young San Diego Jerry Avorn and Karen Tucker Anla and Mark Kingdon Charitable Fund $5,000 – $9,999 Richard A. Konigsberg Susannah Bailin The Altman Kazickas Foundation Emsie and Kyle Kozloff Bank of America Merrill Lynch Judy Hart Angelo Estate of Laurie D. Lima Patricia A. Baran Bank of America Charitable Clare and Kenneth Livak, PhD Bridget Barber Gift Fund Emily and David Livingston, MD Richard Barnett Arnold and Mary Jo Barnett Loews Corporation Tim Barton Family Philanthropic Fund The Luppe And Paula Luppen F. Harlan Batrus Barbara Lieb Baumstein Family Foundation Julie and Roger Baumann The Howard Bayne Fund Susan and Morris Mark Thomas Bean Benevity Community Impact Fund Sam Martini Edna Beaudette Isabel and Steven Berg Jami W. McKeon Jill C. Bee Edgar Berner Family Fund of The Leo Model Foundation, Inc. Kathleen Bellamy the Jewish Community Foundation Jody and John Myers Debra and Marc Bennet BNY Mellon Network For Good Ann and Thomas Berger Ann and Frank Bumstead Perrigo Company Foundation Sandye Berger The Calf Island Foundation Karen C. Phillips The Len and Laura Berlik Russell L. Carson Julie and James Pulk Foundation, Inc. Elizabeth M. Christiansen Richard Reiss Melissa Berman Estate of Laurelia M. Clifford Emily and Michael Repperger Bernard Family Charitable Fund Daniel G. Cohen Lisa and Michael Rome Robert Bernard Paula and Martin Cohen Linda and Jerry Saslow Julia and Edgar Berner The Jodi and Wayne Cooperman John M. Shapiro and Shonni J. Bessemer Trust Charitable Fund Silverberg Philanthropic Fund Karen E. Binkhurst Dorothy D’Amato Suzy Sang Shechtman Eugenie and Robert Birch

38 DAMON RUNYON CANCER RESEARCH FOUNDATION OUR CONTRIBUTORS (CONTINUED)

Bismarck Capital, LLC Danae Cavadias Colleen DeSimone Richard Blair Bryan D. Cavalier Herb Deuschel Mindee Blanco Ellen and Jon Channing Barbara Deutsch, MD Bob Blau Judy Chase Nanci and Harold Deutsch BLL Foundation Chatham Asset Management LLC Alice Diamond Steven Bloch David Chazen Nicholas Didycz Harold Block Jerome A. Chazen Monica Duvall DiLella, MD, Jonathan Block Philip J. Clark and Daniel DiLella David Bloom The Clark Family Private Foundation Dagmar Dolby William Boeh Clayman Raiman Foundation Elizabeth Donahue Nadine E. Bognar Cynthia and Jay L. Cohan Marjorie Doniger The Boisi Family Foundation Charitable Gift Fund Barry L. Dorfman Marilyn Booker Gala Cohen DoubleBlue Capital Management Gail and Richard Bowen The Cohen Family Foundation Robin N. Dracos Bonnie and Thomas Bown II Harvey Coleman James Drought June and Thomas Bracken The Colton Family Foundation Josephine J. Dumm Daniel Brennan Combined Jewish Philanthropies Patricia and Michael Dweck Gloria P. Briggs Communities Foundation of Carol and Dexter Earle Karen and Louis Briskman Texas (CFT) Jennifer and Don Eddington Frank Brosens and Deenie The Coneway Family Foundation Eric Edelstein Brosens Foundation Cara Cook Margaret Engel Janet and Richard Bruce H.J. Cooperman Family Julia Espel and Kenneth Chang Audrey Buchner Charitable Trust The Ettl Family Judy Buechner Advised Fund Teresa and Jim Copenhaver Philanthropic Fund Lisa Bullock Daniel W. Cotten Marilyn and Erwin Ezzes Suzanne and Steven J. Burakoff, MD Elinor and Michael Crames Facebook Edmund S. Burke Brenda L. Crane Eleanor and Thomas J. Fahey, Jr., MD Burlingame Foundation Yvonne B. Craver Lynne Farbman James A. Burns Kristine and Jonathan Crawford Farella Braun & Martel LLP Yvette Calderon Kimberly Creem Phyllis and Samuel Feder Valerie Caproni Betsy and Philip Darivoff Lori and Michael Feldstein Kim Carmack-Muckleroy Lawrence H. David Ilene Fine and Jay Pomerance Lucille and Charles Carothers Spencer Davidson Roberta Fine Bonnie Carpenter Barbara and Robert Davis Nancy A. Federspiel, PhD, Michael Carter Ellen and Pierre de Vegh and Robert F. Fisher, PhD Susan K. Carter Defined Health Terry Fisher Edward Cassel Dennis Delafield Jill and Mark Fishman

Not only has this award had a tremendous impact on my career on a personal level, but it has also allowed us to do some great science and help many patients along the way. A lot of what I have been able to achieve over the past few years simply would not have been possible without your support.

RYAN B. CORCORAN, MD, PhD Damon Runyon Clinical Investigator, 2012–2017 Massachusetts General Hospital

2018 ANNUAL REPORT 39 OUR CONTRIBUTORS (CONTINUED)

David Fleishhacker Judith Gushner and Robert Beber Wayne D. Kent Philip Floyd Julie S. Haggey Sharon K. Kilmer Alan Franco Edmund A. Hajim Jennifer and James Kimenker Roxanne Frank Nanci and Robert Halper Kathryn King Kimberly G. Frankenthal Lynne and Howard Halpern Sue F. King Amy and Wendy Franklin-Willis Meredith and Michael Hammerman Douglas Kinney Arlene Sharpe, MD, PhD, Michael Hanley Gerold F.L. Klauer and Gordon Freeman, PhD Lisa C. Hargrove Lee P. Klingenstein Mary Ann Frenzel Penelope P. Harris Jacqueline and Mitchell Knapp Mary Ann Fribourg Kristy and Robert Harteveldt Abby Kohnstamm Lois Fried Kimberly and Alan Hartman Dorothy Davies and Jeremy Kramer Harold And Elaine The Hartman Family Foundation Krasdale Foods Friedland Foundation Richard L. Haydon Sandra Krause Joseph Frye Elizabeth Hazard Wendy Kreeger FTI Consulting Healey Family Foundation The Krimendahl/Saint-Amand Elaine Fuchs, PhD, and David Hansen Marilyn and Gary Hellinger Foundation Sarah Gannon Olga and Enrique Hernandez J. Kenneth Kruvant Mary and Doyle Garriott Stephen Hess Amy R. Kurland Elizabeth F. Gaudreau William E. Hess and Louise A. Hess Luis Lainer Nancy and Richard Gaynor, MD Charitable Fund Barbara Landau Janet Gelbart Thomas Hesselbrock Elizabeth Landes General Electric Foundation Marion Hindin William D. and E.M. Lane Foundation Cindy and Stan Gersch Deborah Hirtle Ellen S. Lane Wayne Gibbens Jane and R. Lee Hite Janice R. Lane Jean and Robert Gibson, Jr. Ashley and Harriet Hoffman Jasbeena and Ralph Layman Warren Ginsberg The Harold and Ethel Horowitz Elizabeth and Mark Lazarus Alfred S. Glazier Family Charitable Foundation Clarence Lear IV Ken Globus Clair Howey Fabienne Lecole Judith M. Gnys Celia Pohani and Daniel Huber Carolann and Steven Leffler Garry E. Gold Mary I. Hull Tova Leidesdorf Paul D. Goldenheim Mary Gwen and Ben Hulsey David S. Leinwand Goldie Anna Charitable Trust David Humphrey Amy Lejuez Neil Goldmacher Kirsten and Kevin Hungate Lisa Lesavoy Estate of Stephanie Goldman Sheila and Miles Hurwitz Levin Capital Strategies, LP Lawrence Goldrich Phyllis Hyde The Nate and Ann Levine Barbara Goldstein Tom Ike Family Foundation N.S. Goldstein Foundation, Inc. Scott R. Isdaner Jeffrey S. Levitt Arthur H. Goldstone J. Ira and Nicki Harris Betty Levy Goldstone Fund, Inc. Family Foundation Daniel Levy Ellen M. Golub J.I. Foundation, Inc. William Guy and Marcia Levy Charitable Foundation Judith Jaehning, PhD Shoshana and Ronald Levy, MD Martha and Todd Golub, MD Jewish Community Foundation of Estate of Franklin S. Lewis Jose Antonio Gonzalez MetroWest New Jersey Keith Liberman Paul Goodman Jewish Foundation of Greensboro Lisa and Steven Lieberman James S. Gordon Lauren Johnson Stephen Lightman William Grabe Johnson-Miller Foundation Linden Motor Freight Sam Grant Joyce and Stephen Joseph Company, Inc. Elizabeth A. Gray JPMorgan Chase Foundation Susan and Martin Lipton Aileen J. Grebow Marnee Kaltman Mary and Fred Litwin Paul Greenbaum Ed and Ann Kania Foundation Michael Lorusso Judy and Billy Greenblatt Howard Karpoff Frank E. and Miriam Loveman Terri Grodzicker, PhD Shelly and Michael Kassen Foundation Inc. Eleanor Gross Vicki and Samuel Katz Barbara Macklowe Eric Gross Marcia Kaufman Heather and Michael Madden Warren Grover Shari Kaufman Jean and Michael Maher

40 DAMON RUNYON CANCER RESEARCH FOUNDATION OUR CONTRIBUTORS (CONTINUED)

Gail and Richard Maidman Debra and Ronald Parr Larry Rush Alix Mann John Passios Hodgson Russ LLP Marble Fund, Inc. PayPal Charitable Giving Fund Carol Saginaw Michael Marquardt Steven S. Payson Liz Salguero Julie and Gerald Marshall Cindy and Robert Pearlstein Sylvia and Norman Samet Carlos Martir Joan O. Pearlstein The Sylvia L. and Norman G. Samet Ellen Mathias Agnes Peelle Family Philanthropic Fund The August Mattheyses Fund Victoria and Robert Pennoyer Sanderson Family Charitable Fund of the Community Foundation Elizabeth Perry Kim Sands of New Jersey Petruzzelli/Herrera Fund Ilene and Steven B. Sands Helen and Tom May Pfizer Foundation Shamba Sandy MB Real Estate Pfizer Inc. Jane and Angelo Santinelli Christine S. McKiernan Linda McFarlin and Edwin Phelps Family Fund Marni McKinney Joseph Piorkowski Padma and Anand Savur Michael W. McMahon Lori and Larry Pitkowsky Kathleen and James Sayre John McStay Vickie and Rahn Pitzer , PhD Katherine L. Meier Catherine and Leon Pollack Marvin Schildkraut Mark Melchiorre Peter M. Polow, Sr. Norman R. Schlanger Joshua Mellen Greg Poole Harriet P. Schleifer Kathleen and Woodson Merrell, MD Elizabeth Portland and Thomas Toce Henry Scholder Martin Messinger Elizabeth and Tim Portland Mendon F. Schutt Family Fund Carole Middleton Fund Ronnie Potter Eugene P. Schwartz Fred Middleton Sheldon Pressler Family Foundation Louise Middleton Mary and Ron Pressman Harry A. and Joseph Schwartz Payne W. Middleton Carol and David Pulver Family Foundation I. George Miller, MD Paul Purcell and James Souther David Schwartz Laura Miller Steve Pustil Marvin C. Schwartz Suzy, Nancy and Carol Minkoff Richard and Robin Pzena Madeline and Steven Schwartz Charitable Fund Charitable Fund William Scroggins Morgan Stanley Tina Rafowitz Robert Sechan Patty Hogan and Meghan and Ryan Raveis Peggy Segal Sanford Morhouse, Esq. Kimberly and Chris Raveis Marianne Lee and Laurie Morris RBC Wealth Management William Sellers, MD John Murphy, PhD Katherine M. Reeves Ethel G. Sensenig Muffie Bancroft and Joan and John Regan Brian Shapiro W. Stephen Murray Kathleen Reid Felice Shea Miles S. Nadal Diane L. Reidy Barbara Sherman Susan and Kenneth Narva Garrett Reisman Abraham I. and Jean Sherr Herbert Natof, MD Susan Richardson Foundation, Inc. Sarah and Thomas Neff Susan and Jeffrey Rieder Lois Sherwin Susan Neisloss David Rimmer Robert Sherwin New Jersey Performing Arts Center Jane and D. Paul Rittmaster Phyllis Brown Shmalo Jane E. Newman Ed Robbins Susan and Bill Shmerler Sonia and Phillip Newmark, PhD Paula Robichaud Shmerler Foundation, Inc. Nolan Securities Corporation Lori J. Robinson Joan Shore Harriett and Harvey Nusbaum Mary Beth Roche The Sidewater Family William O’Boyle Marian and David Rocker Foundation, Inc. Paula Oppenheim Nancy J. Rocker Steven N. Siegel Susan Orman Karen and Gary Rockhold Gary N. Siegler Jeffrey Ostrove Donor Advised Fund Elizabeth Roddin Karen and Harvey Silverman David Page Miriam K. Rothenberg Patricia Silverstein Barbara and Robert Paget Nina Rothstein Julia Reidhead and Jamil Simon Paisley Family Fund The Roxe Foundation Susan Simon Palisade Capital Management Kimberly Rubin Michael Simonds Catherine Park Steven Rudman Eric Small

2018 ANNUAL REPORT 41 OUR CONTRIBUTORS (CONTINUED)

Amy Smith Daniel Tracy Caroline Werther Jeff Smith Dina Treanor and Jeffrey Taschler Janet and Alan Widra Estate of Lidie Anne Smith Karen Tucker and Jerry Avorn Barbara and David Wiederecht Estate of Mildred A. Smith Jane Turley Byron R. Wien Marie-Noelle and Jeffrey Smith J. Page Turney Allison C. Williams Sarah Snell UBS Financial Services, Inc. George Wilson Nancy and Stephen Snell Steven Urbach Gregory Wilson Garry Snook Kathy Van Camp Eleanor and Benjamin Winter The Sokol Family Gift Fund Mariah Varner Jami McLaughlin and Sharon Sokolow Craig Varrelman, CFA Owen Witte, MD Gerri and Andrew Sommers Elizabeth J. Vega Elaine and Harold Wolchok Vinton H. Sommerville Kathryn Vizas Peggy Wong Philippe Soriano, DSc, PhD Anastasia Vournas Rod Wood Teresa and Kenneth Stabler Linda and Edward Wacks Wright Investors’ Service Dale and Harold Stahler, Esq. Robert Waldbauer Holdings, Inc. Keren and Alex Stankevich Joni Walser and Andrew Church Barbara and Robert Young State Street Foundation The Walt Disney Company Julie Yu Matching Gift Program Judith and Peter Wasserman Gayle and Emmett Zimmerman III Ian Steele The Wasserman Foundation Seymour W. Zises Elizabeth Steidel Waterfall Family Foundation Benjamin Zuckerman Sarah Stenn Georgianna and Robert Waters C. Scotland Stevens Anita and Alan Weber Gloria and Rodney Stone Michele and Donald Weeden Leila and Melville Straus Samuel G. Weinberg Judith Studer Vicki and Victor Weinstein Mark Stueve Wendy Weinstein Diane Sullivan David Weinstock, MD Roy Sutherland David and Candace Weir Foundation T. Rowe Price Trust Co. Carol Windsor and Dorothy Tananbaum James A. Wells, PhD Karen and Sanford Teplitzky Wells Fargo Philanthropic East Patricia and J. Ronald Terwilliger Wells Fargo Wealth Management Tullia Lindsten, MD, PhD, Donald and Barbara and Craig Thompson, MD Werner Foundation

Receiving this Fellowship meant that I could focus my time as a postdoctoral fellow on research instead of applying for grants to fund my work. I am thankful for the opportunity to have connected with so many high-achieving scientists.

ALLISON LAU, Ph D Damon Runyon Fellow, 2015–2019 Massachusetts Institute of Technology

42 DAMON RUNYON CANCER RESEARCH FOUNDATION Broadway Premier Circle

The Broadway Premier Circle is a group of loyal Damon Runyon Broadway Tickets customers who have made a special donation in support of cancer research. The Premier Circle offers members priority access to tickets and other benefits.

David Altshuler Donald Herdrich Paula Robichaud Susannah Bailin The Harold & Ethel Horowitz Family Kimberly Rubin Julie and Roger Baumann Charitable Foundation Jane and Angelo Santinelli Barbara Lieb Baumstein Andre Hunter Linda and Jerry Saslow Jill C. Bee Phyllis Hyde, MD David G. Schwartz Bonnie Bernard Scott R. Isdaner Eugene P. Schwartz Family Julia and Edgar F. Berner Robert Kaplan Foundation Gail and Richard L. Bowen Vicki and Samuel L. Katz Harry A. & Joseph Schwartz Janet and Richard E. Bruce Jennifer and James H. Kimenker Family Foundation Ann and Frank M. Bumstead Kathryn King Madeline and Steven Schwartz Elizabeth M. Christiansen Gerold F.L. Klauer Barbara Sherman Philip J. Clark Richard A. Konigsberg Abraham I. & Jean Sherr Samuel T. Cohen Emsie and Kyle S. Kozloff Foundation, Inc. Dorothy D’Amato Dorothy R. Davies and Lois Sherwin Alyce and Philip DeToledo Jeremy R. Kramer Shmerler Foundation, Inc. Dagmar Dolby Sandra Krause The Sidewater Family Marjorie Doniger Ellen S. Lane Foundation, Inc. Jane and Larry D. Droppa Elizabeth and Mark Lazarus Diane Sullivan Carol and Dexter D. Earle The Nate and Ann Levine Family Jennifer Toll Marian and Robert Ettl Foundation Susan Waterfall Jill and Mark Fishman Marcia D. Levy and William Guy Waterfall Family Foundation Linda Frankel Martin and Susan Lipton Vicki and Victor J. Weinstein, MD Harold And Elaine Friedland Clare and Kenneth J. Livak, PhD Caroline Werther Foundation Frank E. & Miriam Loveman Janet M. and Alan Widra Paul D. Goldenheim Foundation Inc. Jami McLaughlin and N.S. Goldstein Foundation, Inc. Michael W. McMahon Owen N. Witte, MD Sam Grant Carole Middleton Barbara and Robert C. Young, MD Mignon Groch Nancy and Russell C. Minkoff Eleanor Gross Joan O. Pearlstein Nanci and Robert M. Halper, MD Agnes Peelle Penelope P. Harris Clayman Raiman Foundation

Discovery Society

Discovery Society members are valued supporters who have informed us that they have provided for the Damon Runyon Cancer Research Foundation through future planned gifts. These donations provide a vital source of support and fuel future breakthroughs against cancer. If you have made a planned gift to the Foundation, please contact Hilary Rogers at 212.455.0535.

Elaine M. Addis Nancy and Richard B. Gaynor, MD Seymour Rosenheck Judy Chase Rick J. Govern Esther E. and Herbert Schwartz Paula and Martin J. Cohen Georgia M. and William C. Hines William Scroggins Ann K. Cote Rebecca R. Kry Phoebe H. Showers Anne C. Burkholder, PhD, and Linda B. Lloyd and Wallace Specter Stephen P. Eisenberg, PhD Lewis L. Lanier, PhD Carol H. Stix Phyllis Farleigh Catherine and Leo LoFrisco Rose Vaccariello Nancy A. Federspiel, PhD, D.G. Mitchell Jacqueline and Arthur Walker and Robert F. Fisher, PhD Debra L. and Ronald E. Parr Mary Ann Frenzel Lynne and Rick Robinson

2018 ANNUAL REPORT 43 Ways to Give

Online Phone

www.damonrunyon.org/donate 1.877.7CANCER or 1.877.722.6237 9 am–5 pm ET, Monday to Friday

Mail Estate Planning

One Exchange Plaza, 55 Broadway Visit our website for more information: Suite 302, New York, NY 10006 www.damonrunyon.org/get-involved

Damon Runyon Broadway Tickets

Damon Runyon Broadway Tickets offers Broadway’s best seats and the opportunity to support cutting- edge cancer research at the same time. Orchestra seats are available for even the most popular shows.

Join our Premier Circle to Our Gift Certificates are perfect for Call us for tickets and more at enjoy benefits like priority holiday gifts, as well as birthdays, 212.455.0550 between 9 am–5 pm ET, access to tickets before they go anniversaries, or any occasion— Monday to Friday. Purchase tickets online on sale each month, and more. a fun night and a meaningful gift. at www.damonrunyon.org/broadway

44 DAMON RUNYON CANCER RESEARCH FOUNDATION Financial Summary Fiscal Year 2018

As in previous years, the financial activities of the Damon Runyon Cancer Research Foundation were audited by RMS US LLP. Below is a snapshot of FY2018.

For our complete audited financial statements, please visit our website at WWW.DAMONRUNYON.ORG

TOTAL OPERATING EXPENSES TOTAL REVENUE

$22 $22 MILLION MILLION

Award Programs 83.5% Contributions 56.2% Fundraising 14.0% Damon Runyon Broadway Tickets 3.3% General Administration 2.5% Donated Services 3.7% Bequests and Trusts 8.3% Misc. Income 1.0% Allocation from Investments 27.5%

2017 2018 SUMMARY OF Total Assets $142,411,870 $148,707,992 BALANCE SHEETS Total Liabilities $30,256,220 $32,236,227 Total Net Assets $112,155,650 $116,471,765

Our overhead is paid from our endowment and Damon Runyon Broadway Tickets, allowing 100% of your donation to support cancer research.

348814_DRC_Book_CVR_R1.indd 4-6 10/25/18 8:34 PM 100% OF YOUR DONATION FUNDS BRILLIANT SCIENTISTS.

We pay our low overhead from Damon Runyon Broadway THE SCIENCE OF Tickets and our endowment. For more information, visit: WWW.DAMONRUNYON.ORG/GET-INVOLVED LEADERSHIP

Annual Report 2018

ONE EXCHANGE PLAZA 55 Broadway, Suite 302 New York, New York 10006 1.877.7CANCER T 212.455.0500 F 212.455.0509 www.damonrunyon.org

348814_DRC_Book_CVR_R1.indd 1-3 10/25/18 8:34 PM